Document:

Exhibit 10.6

 

AMENDING
AgREEMENT No. 3 TO SHARE PURCHASE AGREEMENT

 

This
Amending Agreement No. 3 to the Share Purchase Agreement is dated March 16, 2020 (the “Amending Agreement No. 3”)
by and among CannaPharmaRx Canada Corp. (the “Purchaser”), CannaPharmaRx, Inc. (the “Purchaser Parent”)
and Sunniva Inc. (the “Vendor”).

 

WHEREAS,
the Purchaser, the Purchaser Parent and the Vendor entered into a Share Purchase Agreement dated June
11, 2019, as amended by an Amending Agreement entered into between such parties dated October 2, 2019 and as amended by
Amending Agreement No. 2 entered into between such parties dated November 27, 2019 (as so amended, the “Purchase Agreement”);

 

AND,
WHEREAS, the Parties wish to enter into this Amending Agreement No. 3 to further amend the Purchase Agreement;

 

NOW,
THEREFORE, in consideration of the foregoing, and for other good and valuable consideration (the receipt and sufficiency
of which is acknowledged by each Party), the Parties agree as follows:

 

Article
1
 INTERPRETATION

 

	Section 1.1	Defined Terms.

 

In this Amending Agreement
No. 3 and the recitals hereto, unless otherwise defined, capitalized terms shall have the meaning given to them in the Purchase
Agreement.

 

Article 2

AMENDMENT TO Purchase Agreement

	Section 2.1	Payment of Purchase Price.

 

Section 2.3 of the
Purchase Agreement is hereby deleted and replaced with the following language:

 

“Section 2.3
Payment of Purchase Price.

 

The Purchase Price shall
be paid and satisfied as follows:

 

		(a)	as to $1,206,418.31 (the “Deposit Amount”), by payment of an amount equal to
the Deposit Amount by the Purchaser to the Vendor in one or more installments, such Deposit Amount to be a non-refundable deposit
against the Purchase Price;

 

		(b)	as to $700,000 (the “Extension Amount”), by payment of the Extension Amount
by the Purchaser to the Vendor on or before October 10, 2019, such Extension Amount to be a non-refundable deposit against the
Purchase Price;

 

 

 

    	 	1	 

     

    

 

		(c)	as to $7,133,374, by delivery to the Vendor on the Closing Date of 3,566,687 Series C Preferred
Shares of the Purchaser Parent (the “Consideration Shares”), such Consideration Shares having the terms and
conditions substantially in the form as set forth in Exhibit “A”; and

 

		(d)	as to an amount equal to $10,960,207.69 less the sum the estimated Closing Indebtedness set out
in the Estimated Closing Indebtedness Statement (as defined below), by payment of such amount by the Purchaser to the Vendor on
the Closing Date.

 

All cash payments under this Section 2.3
will be made by certified cheque, bank draft or wire transfer of immediately available funds to a bank account or bank
accounts specified in writing by the Vendor.”

 

	Section 2.2	Representations and Warranties of the Purchaser and Purchaser Parent.

 

Section 5.1 of the
Purchase Agreement is hereby amended by adding the following clauses after Section 5.1(h):

 

		“(i)	Issuance of Shares.
Neither the issuance of the Consideration Shares nor the issuance of any shares of common stock of the Purchaser Parent issuable
on conversion of the Consideration Shares is accordance with their terms (the “Conversion Shares”) will (i)
require the consent or approval of all or any of the shareholders of the Purchaser Parent, (ii) require the consent, approval,
or authorization, order or agreement of, or registration or qualification with, any Governmental Entity, (ii) result in any breach
or violation of any of the provisions of, or constitute a default under, any indenture, mortgage, deed of trust, lease or other
agreement or instrument to which the Corporation or any of the Designated Subsidiaries is a party or by which any of them or any
of their respective properties or assets is bound or (iii) result in any breach or violation of the Purchaser Parent’s Governing
Documents, any resolutions of the shareholders or directors of the Purchaser Parent or any Contract to which the Purchaser Parent
is a party or by which it is bound. The Consideration Shares, when issued and delivered in accordance with the terms of
this Agreement for the consideration expressed herein, will be validly issued as fully paid and non-assessable shares in the capital
of the Purchaser Parent, and will be free of restrictions on transfer other than restrictions on transfer under applicable Securities
Laws (as defined below). Any Conversion Shares issuable upon the conversion of the Consideration Shares will be duly and validly
authorized, allotted and reserved for issuance upon such conversion and will, upon the conversion of the Convertible Debentures
in accordance with their terms, be validly issued as fully paid and non-assessable shares in the capital of the Purchaser Parent,
and will be free of restrictions on transfer other than restrictions on transfer under applicable Securities Laws.

 

		(j)	Compliance with Securities Laws. The Purchaser Parent (i) is a reporting issuer under the
Securities Laws of each of the Provinces of British Columbia and Alberta and is not on the list of defaulting reporting issuers
(or the equivalent list) maintained by the applicable securities regulatory authorities in any such province, (ii) has filed all
material forms, reports and documents required under Securities Laws with applicable securities regulatory authorities and any
stock exchange on which its securities are listed, as applicable, and (iii) is in compliance in all material respects with applicable
federal, state, provincial securities in Canada and the United States, as applicable, and the respective rules, regulations, blanket
orders and rulings under such laws together with applicable published policies, policy statements, instruments and notices (collectively,
“Securities Laws”).

 

		(k)	Disclosure Record. The material change reports, financial statements, information circulars,
press releases or other continuous disclosure documents filed by or on behalf of the Purchaser Parent under Securities Laws (the
“Public Record”) constitutes all documents required to be filed by the Purchaser Parent under Securities Laws.
At the time it was filed (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such
filing), each of the documents comprising the Public Record (i) complied in all material respects with the applicable requirements
of Securities Laws and (ii) was true, correct and complete in all material respects and did not contain any material misrepresentation
as of the date of such document. There is no “material fact” or “material change” in respect of the Purchaser
Parent (in each case, as those terms are defined under Securities Laws) that has not been publicly disclosed and the Purchaser
Parent has not filed any confidential material change reports which are still maintained on a confidential basis.

 

 

 

    	 	2	 

     

    

 

	Section 2.3	Closing Conditions for the Benefit of the Vendor.

 

Section 8.2 of the
Purchase Agreement is hereby amended by:

 

		(a)	replacing all references to “the Purchaser” in Section 8.2(a), Section 8.2(b) and Sections
8.2(ii), (iii) and (iv) with “the Purchaser and the Purchaser Parent”;

 

		(b)	adding the following clause after Section 8.2(d)(iv):

 

		“(iv)	a certificate representing the Consideration Shares registered in the name of the Vendor;”

 

		(c)	adding the following clause after Section 8.2(e):

 

		“(f)	Series C Preferred Shares. The Purchaser Parent shall have provided the Vendor with evidence
satisfactory to the Vendor that the Series C Preferred Shares have been validly created and have terms and conditions satisfactory
to the Vendor.”

 

	Section 2.4	Extension of Outside Date.

 

Section 10.1(b)(ii)
of the Purchase Agreement is hereby deleted and replaced with the following language:

 

		“(ii)	if any of the items set
forth in Section 8.1 have not been delivered or waived on or prior to March 31, 2020 (the “Outside Date”),
or it becomes reasonably apparent that any of such deliveries will not be satisfied on or before the Outside Date (other than as
result of the failure of the Purchaser to perform any of its obligations under this Agreement) and the Purchaser has not waived
such conditions in writing on or prior to the Outside Date.”

 

Article 3

MISCELLANEOUS

 

	Section 3.1	Time of the Essence.

 

Time is of the essence
in this Amending Agreement.

 

	Section 3.2	Amendments.

 

This
Amending Agreement may only be amended, supplemented or otherwise modified by written agreement signed by the Purchaser and the
Vendor.

 

	Section 3.3	Further Assurances.

 

From time to time after
the Closing Date, each Party shall, at the request of any other Party, execute and deliver such additional conveyances, transfers
and other assurances as may be reasonably required to effectively carry out the intent of this Amending Agreement.

 

	Section 3.4	Purchase Agreement Remains in Force.

 

Except as hereby amended
and supplemented by this Amending Agreement, the Purchase Agreement remains in full force and effect.

 

 

 

    	 	3	 

     

    

 

	Section 3.5	Successors and Assigns.

 

	(1)	This Amending Agreement becomes effective only when executed by all of the Parties. After that
time, it will be binding upon and enure to the benefit of the Parties and their respective successors and permitted assigns.

 

	(2)	Neither this Amending Agreement nor any of the rights or obligations under this Amending Agreement
may be assigned or transferred, in whole or in part, by any Party without the prior written consent of the other Parties.

 

	Section 3.6	Severability.

 

If any provision of
this Amending Agreement is determined to be illegal, invalid or unenforceable by an arbitrator or any court of competent jurisdiction,
that provision will be severed from this Amending Agreement, and the remaining provisions will remain in full force and effect.

 

	Section 3.7	Entire Agreement.

 

The Purchase Agreement,
as amended by this Amending Agreement, constitutes the entire agreement between the Parties with respect to the transactions contemplated
by the Purchase Agreement and this Amending Agreement and, as so amended, supersedes all prior agreements, understandings, negotiations
and discussions, whether oral or written, of the Parties with respect to the subject matter hereof and thereof. There are no representations,
warranties, covenants, conditions or other agreements, express or implied, collateral, statutory or otherwise, between the Parties
in connection with the subject matter of the Purchase Agreement and this Amending Agreement, except as specifically set forth in
the Purchase Agreement and this Amending Agreement. The Parties have not relied and are not relying on any other information, discussion
or understanding in entering into this Amending Agreement and completing the transactions contemplated by the Purchase Agreement
or this Amending Agreement.

 

	Section 3.8	Governing Law.

 

	(1)	This Amending Agreement is governed by and will be interpreted and construed in accordance with
the laws of the Province of British Columbia and the federal laws of Canada applicable therein.

 

	(2)	Each Party irrevocably attorns and submits to the non-exclusive jurisdiction of the courts of British
Columbia situated in the City of Vancouver and waives objection to the venue of any proceeding in such court or that such court
provides an inappropriate forum.

 

	Section 3.9	Counterparts.

 

This
Amending Agreement may be executed in any number of counterparts, each of which is deemed to be an original, and such counterparts
together constitute one and the same instrument. Transmission of an executed signature page by facsimile, email or other electronic
means is as effective as a manually executed counterpart of this Amending Agreement.

 

[Signature page follows.]

 

 

 

    	 	4	 

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Amending Agreement as of the date first set forth above.

 

 

	CANNAPHARMARX CANADA CORP.
	 	 
	By:	/s/ Dominic Colvin
	 	Name:
        Dominic Colvin
	 	Title: President and CEO
	 	 
	 	 
	 	 
	 	 
	CANNAPHARMARX, INC.
	 	 
	By:	/s/ Dominic Colvin
	 	Name:
        Dominic Colvin
	 	Title:
        President and CEO
	 	 
	 	 
	 	 
	 	 
	SUNNIVA INC.
	 	 
	By:	/s/ Anthony Holler
	 	Name: Anthony Holler
	 	Title: Chief Executive Officer

 

 

 

 

 

    	 	5	 

     

    

 

Exhibit “A”

 

Indicative Terms and
Conditions of Series C Preferred Shares

 

Pursuant to authority
expressly granted to the Board of Directors of the Corporation by the provisions of the Certificate of Incorporation of the Corporation,
the Board of Directors of the Corporation hereby creates and authorizes the issuance of a series of shares of Preferred Stock of
the Corporation designated as “Series C Convertible Preferred Stock” and hereby fixes the following designation and
number of shares of such series and the following voting, dividend rate, liquidation preference, redemption, conversion right and
other rights, preferences and restrictions with respect to such series:

 

(1)          Number
of Shares; Designation. This series of Preferred Stock shall be designated as “Series C Convertible, Redeemable Preferred
Stock” and the number of shares of such series shall be 3,566,687 shares.

 

(2)          Stated
Value. The stated value of the Series C Convertible, Redeemable Preferred Stock shall be $2.00 (CAD) per share.

 

(3)          Dividends.
The holders of outstanding Series C Preferred Stock shall be entitled to receive an 8% cumulative dividend which shall accrue until
such time as, and be payable in cash when, the Series C Preferred Stock is redeemed or converted into Common Stock pursuant to
the terms included herein.

 

(4)          Preference
on Liquidation. In the event of any liquidation, dissolution or winding up of the Corporation, the holders of Series C
Preferred Stock then outstanding shall be entitled to a preference of Stated Value and accrued dividends payable out of the assets
of the Company available for distribution, subordinated to the Preferred Shares previously issued but superior to the Company’s
Common Stock.

 

(5)          Voting
Rights. The Series C Preferred Stock shall not have voting rights.

 

(6)          Conversion
of Series C Convertible Preferred Stock into Common Stock

 

(a)          Any holder of a share or shares of Series C Preferred Stock desiring to convert all or any portion of such Series C Preferred
Stock (including accrued dividends) into Common Stock may do so at any time upon ten (10) business days written notice to the
Company. The Conversion Price shall be equal to the Volume Weighted Average Price (VWAP) of the Common Stock trading on the OTCQX
or any other exchange that the Company may list on, for the period of twenty (20) trading days preceding the date of conversion.
In the event the VWAP is calculated in USD, then the Conversion Price shall be converted to CAD$● being the Canadian dollar
equivalent of US$● based on the Bank of Canada daily exchange rate on the date of Closing of the acquisition of Sunniva
Medical, Inc.

 

(b)          In
the event that the Company shall at any time subdivide or combine in a greater or lesser number of shares the outstanding shares
of Common Stock, the number of shares of Common Stock issuable upon conversion of the Series C Preferred Stock shall be proportionately
increased in the case of subdivision or decreased in the case of a combination, effective in either case at the close of business
on the date when such subdivision or combination shall become effective.

 

 

 

    	 	6	 

     

    

 

(c)          In
the event that the Company shall be recapitalized, consolidated with or merged into any other corporation, or shall sell or convey
to any other corporation all or substantially all of its property as entirety, provision shall be made as part of the terms of
such recapitalization, consolidation, merger, sale or conveyance so that any holder of Series C Preferred Stock may thereafter
receive in lieu of the Common Stock otherwise issuable to him upon conversion of his or her Series C Preferred Stock, but at the
conversion ratio stated herein, the same kind and amount of securities or assets as may be distributable upon such recapitalization,
consolidation, merger, sale or conveyance, with respect to the Common Stock of the Company.

 

(d)          Such adjustments shall be made
successively if more than one event listed in (a) through (c) above shall occur.

 

(7)          Redemption. 

 

(a)          Subject
to the approval of any underwriter, placement agent or lender, in the event that the Company raises greater than $3,000,000 (US)
in equity or debt, the holders of the Series C Preferred Stock may thereafter force the retraction of the number of Series C Preferred
Stock at the Stated Value of the Series C Preferred Stock so redeemed, plus accrued dividends, which together equal not more than
35% of the total funds raised. This right shall continue in respect of all future debt or equity financings until all Series C
Preferred Stock and accrued interest are repaid. The Company shall exert a good faith effort to obtain the required consent.

 

(b)          At
any time after providing ten (10) business days’ notice to the holders of the Series C Preferred Stock, the Company may
redeem all or any portion of the Series C Preferred Stock at the Stated Value of the Series C Preferred Stock so redeemed, plus
accrued dividends.

 

 

 

 

 

 

 

 

 

    	 	7EX-10.1

 Exhibit 10.1 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND
(2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 COVANCE MASTER SERVICES AGREEMENT 

This Master Services Agreement is effective as of March 12, 2020 (“Effective Date”) by and between 

 

	(1)	 Covance Inc. whose registered office is at 206 Carnegie Center, Princeton, NJ 08540 USA (the
Company); and 

  

	(2)	 Galectin Therapeutics Inc. whose registered office is at Suite 240, 4960 Peachtree Industrial Boulevard,
Norcross, Georgia 30071 USA (the Sponsor). 

 (each a Party and collectively the Parties). 

RECITALS 
  

	(A)	 WHEREAS, the Sponsor develops drugs. 

 

	(B)	 WHEREAS, Company, through itself and its Affiliates (as defined below), provides a wide range of product
development and testing services on a worldwide basis to the biotechnology, pharmaceutical and medical device industries, including, without limitation, preclinical efficacy and safety laboratory services, Phase I, II, III and IV clinical services,
periapproval services, central laboratory services, health economics services, market access and commercialization and biotechnology services. 

  

	(C)	 WHEREAS, the Sponsor desires to contract with Company and/or its Affiliates for the purpose of providing
services to assist the Sponsor in the execution of various projects. 

  

	(D)	 WHEREAS, when the Sponsor requests the services of the Company or any of its Affiliates, and the Company or its
Affiliate is able to provide such services, the relevant parties shall enter into a separate service contract in accordance with this Agreement (as defined below). 

 

	(E)	 WHEREAS, each such separate contract shall be a Work Order (as defined below) each of which shall incorporate
the terms and conditions set out in this Agreement. 

 IT IS AGREED 

 

	1	 DEFINITIONS

  

	1.1	 In this Agreement, unless the context otherwise requires, the following words and expressions shall have the
following meanings: 

 “Affiliate” means any entity controlling, controlled by, or in common control with
a Party. For the purposes of this definition, “Control” shall mean ownership or control, directly or indirectly of more than fifty per cent (50%) of the common voting stock or ordinary shares in the entity or the right to appoint
fifty per cent (50%) or more of the directors of that entity. With respect to the Company, the term Affiliate shall include Laboratory Corporation of America Holdings and any business entity that is controlled by or under common control with
Laboratory Corporation of America Holdings. 

  

			
	Page 1 of 60

 “Agreement” means this MSA and any applicable Exhibit A. 

“Anti-Corruption Laws” means any anti-bribery and anti-corruption laws, rules, regulations applicable to either Party (each as
amended from time to time) including the Prevention of Corruption Act (Cap. 241) of Singapore, the US Anti-Kickback Law, the US Foreign Corrupt Practices Act, the UK Bribery Act 2010 and the OECD Convention Against the Bribery of Foreign Government
Officials in International Business Transactions, together with any applicable implementing legislation, including any applicable local law addressing bribery or corruption. 

“Assumptions” means any General Assumptions and any Study/Services Specific Assumptions. 

“Background IP” means all pre-existing intellectual property belonging to or licensed
to a Party or other intellectual property created outside the scope of the Services. 
 “Budget” means the fees and
estimated pass through costs charged and/or incurred by Covance in the performance of the Services or Study as set out in a Work Order. 

“CFR” mean the US Code of Federal Regulations. 

“Change Order” has the meaning given in Section 10. 

“Claim” means any third party claims, demands, assessments, actions, suits, proceedings, settlements or investigations. 

“Confidential Information” means any and all commercial or technical information or materials and all derivatives thereof, in
any and all forms, howsoever disclosed or obtained including business plans, financial information, client lists and requirements, techniques, designs, methods, processes and procedures which: (i) is identified by a suitable legend or other
marking as being confidential (or similar designation) in a suitable prominent position; (ii) is described as confidential at the time of disclosure; or (iii) the Receiving Party regards or should reasonably be expected to regard as
proprietary and confidential given the nature of the information and the reasonable efforts under the circumstances used to maintain its confidentiality; and any improvements, enhancement or modification made, conceived or developed thereto. 

“Covance” means the Company and each Company Affiliate that signs an Exhibit A and thereby becomes a Party to this Agreement.

 “Covance Property” means inventions, proprietary processes, software (including codes) data, technology, know-how and other intellectual property that have been independently developed, discovered or licensed by Covance, including those that relate to the proprietary innovative testing procedures, laboratory testing,
data collection or data management, procedural manuals, delta flags, nucleic acid based vectors, analytical procedures and approaches (even if such are developed in the course of providing the Services or are captured in documents pertaining to the
Services i.e. laboratory notebooks), techniques, skills, models, multimedia source codes, non-product specific components of questionnaires, management tools and any other materials, employed, developed or
obtained by Covance, which are developed independently and not developed as a result of the Services or a Work Order, or based on the Sponsor’s Confidential Information. 

  

			
	Page 2 of 60

 “Data Protection Laws” mean all applicable privacy, data protection or similar
laws and regulations anywhere in the World, as the same may be amended from time to time, including to the extent applicable to the respective Services, the Data Protection Directive (95/46/EC), the Personal Data Protection Act 2012 of Singapore and
any applicable implementing legislation or any amendment thereto and especially from 25 May 2018, the EU Personal Data Regulation (2016/679/EU) (which repeals Directive 95/46/EC) and the EU Personal Data Directive (2016/680/EU). 

“Delay” means a delay, suspension or postponement of the Services and “Delayed” shall be construed
accordingly. 
 “Deliverables” means as applicable to the Services, Results, Study Records or any other deliverable
specified in the Work Order (including physical products). 
 “Disclosing Party” means a Party that discloses Confidential
Information. 
 “Exhibit A” means the additional terms and conditions of a Company Affiliate which is executed by the
Sponsor and a Company Affiliate and attached to this MSA. If more than one Company Affiliate is a party to this MSA, Exhibit A shall be numbered sequentially beginning with Exhibit A-1 and continuing as
necessary. 
 “FDA” means the US Food and Drug Administration. 

“Financial Interest Claims” means any claims related to the financial interest of a third party with whom the Sponsor has
entered into an agreement for the development, licensing, and/or commercialization of the Test Materials and who has a financial interest in the outcome of the development of such Test Materials. 

“Force Majeure Event” means any force majeure event as recognized by applicable law, but for the purposes of this Agreement,
shall include all circumstances or causes beyond the reasonable control of a Party, including war, threat of war or warlike conditions, blockade, embargo, fire, explosion, lightning, storm, drought, flood, earthquake or other natural disaster,
pandemic or epidemic, power failure, shortage of labor or supplies, supply chain issues, strikes, lock outs, acts of terrorism, riot, civil unrest, insurrection, acts of government or other international bodies, political subdivision and any other
events which by nature could not have been foreseen by the Parties or, if it could have been foreseen, were unavoidable by a reasonable prudent business. 

“General Assumptions” means (i) the scope of the Services remains constant; (ii) the Sponsor timely performs all of
its obligations under this Agreement and any applicable Work Order; (iii) the full cooperation of the Sponsor and any third party not under Covance’s reasonable control in the timely performance of Covance’s obligations under this
Agreement and any applicable Work Order; (iv) the Sponsor refrains from any actions, inactions or omissions that would prevent Covance from performing its obligations in a timely manner; (v) the proper and timely performance of all
appropriate tasks relevant to the Services by third parties outside of Covance’s reasonable control; and (vi) no other event or occurrence outside of Covance’s reasonable control including Force Majeure Events or a change in
Regulatory Requirements which affects the Study. 
 “HBS Donor” means an individual, living or deceased, from whom the HBS
was obtained. 
 “Human Biological Samples” or “HBS” means any human biological material, including human
bodily parts and organs in whole or sub-samples, any tissue, skin, bone, muscle, connective tissue, blood, cerebrospinal fluid, cells, gametes or sub-cellular
structures, such as DNA, or any derivative or product of such human biological materials including stem cells, cell lines, bodily fluids, blood derivatives and urine. 

  

			
	Page 3 of 60

 “IEC/IRB” means an independent ethics committee or institutional review board.

 “Informed Consent” means an IEC/IRB approved informed consent form signed by the HBS Donor, their next of kin or legal
representative authorizing the Use of their HBS. 
 “Invention” means any patentable invention or other registerable
intellectual property rights discovered, conceived or made by Covance specifically as a result of performing the Services for the Sponsor and directly relating to the Test Materials and/or the Sponsor Information. For the avoidance of doubt, any
commercially available methods, processes or assays provided by or on behalf of Sponsor shall not be deemed to be Inventions or Sponsor Information for the purpose of this Agreement. 

“Investigator” means third party principal investigators and/or investigative sites. 

“Loss” means any loss, cost, damage or expense (including reasonable legal expenses). 

“MSA” means this master services agreement document. 

“Personal Data” shall have the meaning set forth in any applicable Data Protection Legislation. 

“Protocol/Scientific Plan” means a protocol or an equivalent document, which includes a scientific plan, laboratory testing
procedure or sample analysis outline, whether provided by the Sponsor or prepared by Covance under the Sponsor’s direction in relation to the Services, the Study and/or relevant Work Order. 

“Receiving Party” means a Party that receives Confidential Information. 

“Regulatory Authority” means any national or state (in the case of the US), or local agency, authority, of any government of
any country having jurisdiction over the respective activities contemplated by this Agreement or Work Order, or over the respective Parties. 

“Regulatory Requirements” means all laws, statutes, acts, rules, regulations, codes, orders, directives or other
legally binding requirements of any Regulatory Authority and industry standards or codes of conduct applicable to the Services. 

“Results” mean: (i) all materials, data, documents and information produced or developed by Covance specifically as a
result of the Services and related to the Test Materials and/or the Sponsor Information; and (ii) the Study Records (if applicable). 

“Samples” means biological samples associated with the Services. 

“Serious Breach” means a reportable non-compliance issue that significantly and
negatively: impacts: (i) the safety or rights of an individual in a Study or (ii) the reliability and robustness of the data generated in a Study. 

“Services” means the services and/or applicable products provided by Covance to the Sponsor as more particularly described in
the Work Order. 
 “Sponsor Information” means Test Materials, data, specification or other materials or information
supplied by the Sponsor to Covance in connection with the Services. 
 “Study” means a clinical trial or scientific
evaluation of the Test Materials to which the Services relate as further defined in the applicable Work Order and Protocol/Scientific Plan. 

  

			
	Page 4 of 60

 “Study/Services Specific Assumptions” means Study or project specific
assumptions set forth in the applicable Work Order. 
 “Study Records” means in relation to contracted activities, all
records, notes, reports (including case report forms; monitoring logs; data correction forms; case histories; medical images; drug safety records; records of receipt, use, processing and disposition of Test Materials and trial master file) and other
observations, notations or data of activities or procedures (in each case whether in a written or electronic format) which Covance obtains from each Investigator or which Covance specifically generates or produces for the relevant Study under the
Regulatory Requirements, excluding the Study subject’s personal medical records. 
 “Subcontractor” means a third party
service provider approved, qualified, reviewed and contracted by Covance for services that are generally provided directly by Covance and which are part of the Services within the scope of this Agreement or a Work Order. 

“System Data” means control data from laboratory tests or transactional, volume and performance data related to the Services,
which does not contain any: (i) data following treatment with any Test Materials; (ii) personally identifiable information; or (iii) Sponsor Confidential Information. 

“Taxes” means VAT/GST, local, state (in the case of the US), federal sales or use taxes, excise taxes, import tax, country
specific business or professional services tax or similar tax on international services or foreign entities providing services or consumption taxes. 

“Test Materials” means compounds, materials, other substances, devices, products or other specific items as described in the
Work Order and/or Protocol/Scientific Plan to be tested or used in the performance of the Services as provided to Covance by the Sponsor or that are the subject of the Services. 

“Use” (in the context of Section 25) means collection, storage (including retention period) transfer (including import
and export), use and return or disposal of HBS including by commercial organizations. 
 “VAT/GST” means value added tax or
goods and services tax. 
 “Vendor” means third-party service providers other than a Subcontractor: (i) that the
Sponsor requires Covance to use; or (ii) used by Covance that are ancillary to or outside Covance’s business activities. Vendors include, third party service providers of electronic data capture/bedside data capture services, specialist
referral laboratories, electrocardiogram services, interactive response technology/voice response services, drug depot and drug supply services, patient recruitment services, transcription services and translation services, providers of equipment or
medical devices, adjudication services, medical imaging services, 24 hour medical coverage telephone line rental, external meeting planners, third party site networks and organisations, regulatory support services and courier services.  

“Work Order” means an individual project agreement in the form of Exhibit B or such other mutually agreed upon form between
the Sponsor and Covance containing details of the Services to be provided by Covance, the Budget, any Study/Services Specific Assumptions and any additional terms, conditions or other particulars applicable to the Services. 

 

	1.2	 In this Agreement, unless the context otherwise requires, references to: (a) Exhibit and Section headings
are inserted for convenience only and do not affect the construction or interpretation of this Agreement; (b) defined terms used in this Agreement, and any Work Order shall have the meanings in this Agreement or the relevant Work Order;
(c) a particular law or statutory provision is a reference to it as it is in force for the time being taking account of any amendment, 

  

			
	Page 5 of 60

	 	
extension, or re-enactment and includes any subordinate legislation for the time being in force made under it; (d) writing or written
includes faxes and e-mail; (e) a person includes a corporate or unincorporated body; (f) one gender includes all genders; (g) including, include, in particular or any
similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms; and (h) words in the singular include the plural and vice versa. 

 

	1.3	 If this Agreement is translated, the English language text and version shall prevail. 

 

	2	 FORM OF CONTRACT 

 

	2.1	 The additional terms and conditions that apply to the services provided by Company or a Company Affiliate (and
any Work Orders thereunder) are detailed in Exhibit A. Upon execution of the relevant Exhibit A, the respective Company Affiliate shall become an additional party to this Agreement and shall be subject to the terms and conditions herein.

  

	2.2	 Each Company Affiliate that enters into a Work Order shall be bound by all applicable terms and conditions of
this Agreement and of the respective Work Order to provide the relevant Services. For the avoidance of doubt and as defined above “Covance” means the Company and any Company Affiliate. Each Company Affiliate who is a Party to this
Agreement shall have the respective rights and obligations of the Company under this Agreement. 

  

	2.3	 The terms and conditions of this Agreement shall apply to the Work Order to the exclusion of any other terms
that the Parties may seek to impose or incorporate or which are implied by trade, custom, practice or course of dealing. 

  

	2.4	 Each Work Order shall: (a) be entered into by Covance and the Sponsor; (b) constitute a separate and
independent contract that binds the relevant Parties; (c) incorporate the terms and conditions of this Agreement, except to the extent as otherwise agreed by the Parties; (d) incorporate by reference the Protocol/Scientific Plan which
shall be deemed part of the Work Order; (e) specify the Services to be provided; (f) specify any conditions and any information required for the Services; (g) be governed by the governing law of this MSA; and (h) specify the
Budget for the Services and any Study/Services Specific Assumptions relating to the Budget together with a payment schedule or payment terms. 

  

	2.5	 The Sponsor acknowledges and agrees that: (a) all issues and correspondence regarding the performance of
such Services should be directed to the relevant person as set out in the applicable Work Order or otherwise identified by Covance; and (b) the relevant Company Affiliate shall be solely responsible and liable to the Sponsor for any breach of
the relevant Work Order. 

  

	2.6	 Each relevant Protocol/Scientific Plan forms part of (and is incorporated into) this Agreement. In the event of
a conflict between the Protocol/Scientific Plan and this Agreement or Work Order, the terms of the Protocol/Scientific Plan shall prevail with respect to the scientific, medical, technical and regulatory guidelines used in the conduct of the
Services. This Agreement and the Work Order shall govern in all other instances. 

  

	2.7	 If there is a conflict between the provisions of this MSA, Exhibit A and the provisions of a Work Order and its
attachments and except to the extent that a provision with a lower priority expressly states otherwise, whereby such provision shall have a higher priority, the conflict shall be resolved by interpreting the provisions in the following order of
priority: this MSA, Exhibit A, the provisions of the Work Order and any other attachments. 

  

			
	Page 6 of 60

	3	 PERFORMANCE AND PROVISION OF SERVICES AND/OR PRODUCTS 

 

	3.1	 Covance: 

(a) Shall perform the Services with due skill and care in accordance with industry standards and the Protocol/Scientific Plan; 

(b) Shall supply the Services, including any applicable products, in accordance with this Agreement and any express terms set out in the Work
Order and the Protocol/Scientific Plan; 
 (c) Represents that Covance’s databases to be used by it for the tracking, handling,
recording, reporting and transmitting of data generated during the performance of the Protocol/Scientific Plan have been fully verified and validated according to applicable industry standards; 

(d) Represents that it is not a party to any agreement that would prevent it from fulfilling its obligations under this Agreement. 

(e) Represents that it has the experience, capability and resources, including but not limited to sufficient personnel to perform the Services
under any Work Order in a competent manner and that it shall at all times devote the necessary personnel to perform the Services in a competent manner. 
  

	3.2	 Represents that it will provide Services and conduct all activities pursuant to this Agreement in accordance
with all applicable laws, regulations and applicable guidance documents, including without limitation, 21 C.F.R. Section 312 and the International Conference on Harmonization Good Clinical Practice Guidelines and including all requirements on
clinical research organizations, including as designees of trial sponsors that relate to Services provided thereunder. 

  

	3.3	 Covance shall use its commercially reasonable efforts to perform the Services within the timeframe estimated in
the Protocol/Scientific Plan or applicable Work Order and within the Budget established under the applicable Work Order. Sponsor agrees and acknowledges that time estimate assumes the full cooperation of the Sponsor, Regulatory Authorities,
IECs/IRBs and Investigators (if applicable) and other third parties not under Covance’s reasonable control. Covance shall notify Sponsor promptly whenever it becomes aware that timeframes and Budgets may not be met, and Covance shall regularly
communicate with Sponsor about steps that can be taken to achieve the applicable timeframes and Budgets and to mitigate any deviations from such timeframes and Budgets. 

 

	3.4	 Covance reserves the right to refuse to perform any Services including in relation to the Test Materials deemed
by Covance, in its sole discretion, as hazardous in nature. 

  

	3.5	 Covance does not warrant or represent that the results of the Study will be acceptable to any regulatory
authority or governmental agency to which they are presented or that the results of the Study will enable Sponsor to further develop, market or otherwise exploit the Test Materials or any other product or service. 

 

	3.6	 Each Party is authorized to enter into this Agreement and that its execution, delivery and performance of this
Agreement will not conflict with or constitute a default under any other agreement to which it is a party or by which its assets are bound. 

  

			
	Page 7 of 60

	4	 TERM 

  

	4.1	 This Agreement shall come into force on the Effective Date and shall remain in force for five
(5) years. Thereafter, this Agreement shall renew automatically for successive one (1) year periods unless a Party provides the other Party with written notice of its intention not to renew and extend this Agreement,
such notice shall be served at least sixty (60) days prior to the commencement of any such renewal term. 

  

	4.2	 Each Work Order shall come into force on the last date of execution by the Parties or such date as specified in
the Work Order and shall continue until the earlier of: 

 (a) expiry of the period specified in the Work Order (or such
extended period as the Parties may agree in writing); or 
 (b) completion of Covance’s provision of the Services (excluding archival
obligations and similar ongoing obligations which would survive in accordance with this Agreement and the respective Work Order) and the Sponsor’s payment of the relevant fees, pass through costs and other applicable costs and expenses incurred
by Covance in the performance of the Services; or 
 (c) termination of this Agreement or the Work Order pursuant to Section 21. 

 

	5	 REGULATORY COMPLIANCE 

 

	5.1	 Each Party shall comply in all material respects with all applicable Regulatory Requirements relevant to the
Services and applicable to the location of the Services to be provided and as may be specified in the respective Work Order or Protocol/Scientific Plan. In the absence of an agreed Protocol/Scientific Plan that is applicable to the Services, the
Sponsor shall notify Covance of the intended regulatory use (if any) of the Services and the applicable Regulatory Requirements to be followed by Covance in performing the Services. 

 

	5.2	 In the event of a conflict in any applicable Regulatory Requirements, the Sponsor shall designate which
regulations shall be followed by Covance in its performance of the Services and the Sponsor shall be fully responsible and shall indemnify Covance for the outcome of such a decision. In the event that Covance cannot perform the Services in a Work
Order as directed by the Sponsor under the Regulatory Requirements or which would place the Parties at risk of a potential Serious Breach, the Parties shall work together to agree what actions should be taken to resolve the conflict. If the Parties
cannot resolve the conflict, Covance reserves the right to Delay or terminate any Services potentially at risk. 

  

	5.3	 If any Regulatory Requirements are changed, upon notification by the Sponsor of such change, Covance shall use
its reasonable commercial efforts to satisfy such new requirements. In the event that compliance with such new requirements necessitates a change in this Agreement or a Work Order, the Parties shall agree in writing on a Change Order prior to
performing any new or revised Services. 

  

	6	 PROTOCOL/SCIENTIFIC PLAN 

 

	6.1	 Covance shall, if required and at the Sponsor’s request and expense, consult with the Sponsor and assist
the Sponsor in developing the Protocol/Scientific Plan and the design of the Services consistent with current Regulatory Requirements. Notwithstanding such assistance, Covance does not warrant that the Protocol/Scientific Plan, Study design or
Results shall satisfy the requirements of any Regulatory Authority at the time of submission. 

  

			
	Page 8 of 60

	6.2	 The Protocol/Scientific Plan shall, to the extent applicable to the Services, specify the Study design,
estimated duration, any Regulatory Authority and the country or countries to which the Sponsor intends to submit the Results and other matters pertinent to the completion of the Study or Services. Covance shall perform the Services for the Sponsor
in accordance with such Protocol/Scientific Plan and the respective Work Order. 

  

	7	 TEST MATERIALS 

 

	7.1	 If applicable to the Services, the Sponsor shall provide Covance with sufficient amounts of any Test Materials
which shall be properly packaged and (except to the extent that labelling is included within the Services under a Work Order) labelled in compliance with any Regulatory Requirements. The Sponsor shall also provide Covance with all applicable,
relevant, accurate and duly authorized Sponsor Information as may be required by Covance to perform the Services, which relates to the Test Materials, including the purity, stability, batch number, storage, transportation and safety requirements or
other relevant information known by the Sponsor. 

  

	7.2	 Sponsor must provide Covance with all available information regarding known or potential hazards associated
with the use of any substances supplied to Covance by Sponsor prior to execution of a Work Order. As an ongoing obligation, Sponsor will promptly notify Covance of the emergence of information impacting the safety of Study subjects or which
otherwise impacts the toxicity assessment or risk profile of the Study product. 

  

	7.3	 Sponsor represents and warrants that all necessary approvals required under Regulatory Requirements will be
obtained prior to the shipment of Test Materials. 

  

	7.4	 Where the nature of the Test Materials requires additional services (including risk assessment and
documentation of genetically modified organisms, radiolabelled material or material requiring import or export permits), Covance reserves the right to levy a mutually agreed charge to the Sponsor for such additional services. 

 

	7.5	 Upon completion of the Services, and unless otherwise agreed in the Protocol/Scientific Plan, any remaining
Test Materials shall, at the Sponsor’s expense, be destroyed or, upon the Sponsor’s request and expense, returned to the Sponsor for retention in compliance with applicable Regulatory Requirements. 

 

	7.6	 The Sponsor represents and warrants that the use of any Sponsor Information or Test Materials by Covance in
performing the Services shall not knowingly infringe the intellectual property rights or breach a party’s confidentiality obligations to a third party. 

  

	7.7	 Covance expressly disclaims: (a) any responsibility and liability for the accuracy of the Sponsor
Information; and (b) any error or defect in the Services as a consequence of any inaccuracies in the Sponsor Information, and in each case Covance disclaims any responsibility and liability for any consequences of such errors or defects.

  

	7.8	 Covance makes no representation, warranty or guarantee regarding the value, prospects, performance, clinical or
commercial success of any Test Material which is the subject of any Services performed by Covance, including the likelihood of such Test Material reaching any particular phase of development, obtaining any regulatory approval, or obtaining any level
of sales or market acceptance. 

  

			
	Page 9 of 60

	8	 FEES AND INVOICES 

 

	8.1	 The Budget and the payment schedule or payment terms for the Services or a Study shall be detailed in a Work
Order. The Budget shall be based on the scope of work, the fees, estimated pass through costs and the Assumptions which apply to the Services. 

  

	8.2	 In consideration for the Services provided by Covance under the applicable Work Order, the Sponsor hereby
agrees to pay Covance the fees and actual pass through costs incurred as specified in the applicable Work Order. Invoices shall be issued in accordance with the payment schedule or payment terms, in the Work Order. 

 

	8.3	 The Sponsor shall pay Covance’s invoices within thirty (30) days of the invoice date. Documentation
for out of pocket expenses shall be provided via a summary report or detailed on the applicable invoice. Detailed expense reports or back-up documentation including actual expense receipts shall not be
provided. If requested by Sponsor on an exceptional basis with reasonable advance written notice or as otherwise agreed under an applicable Work Order [*] for up to [*] per year per project shall be provided by Covance, requests for [*] in excess of
[*] per project per year will be subject to an administrative fee of [*]. 

  

	8.4	 If the Sponsor disagrees with the accuracy of an invoice, the Sponsor shall notify Covance of such inaccuracy
within twenty-five (25) days of receipt of the invoice. Moreover, the Sponsor agrees to pay the amounts for any items not in dispute and agrees not to unreasonably withhold payment. Payments received after [*] of receipt of invoice may be
subject to interest computed at the rate of [*]. 

  

	8.5	 If the Sponsor requires a purchase order for the payment of Covance invoices, the Sponsor shall provide the
purchase order at the time of returning the signed Work Order. Failure to provide a purchase order shall not preclude Covance from issuing an invoice in accordance with the payment schedule or payment terms, defined in the Work Order for milestones
met or work performed and the Sponsor shall be responsible for payment of all invoices. 

  

	9	 TAXES 

  

	9.1	 The Budget for the Services under this Agreement shall not be construed to include any Taxes. Such Taxes now
known or which may come to be known at a later time will be assumed by Sponsor without deduction to amounts owed to Covance. 

  

	9.2	 Payments made by the Sponsor to Covance under this Agreement shall be inclusive of any VAT/GST, where
applicable. Where VAT/GST is properly chargeable on the Services provided under this Agreement and Work Order, the Sponsor shall pay such amounts of VAT/GST to Covance on receipt of a valid tax invoice issued in accordance with the laws and
regulations of the country in which the VAT/GST is chargeable. 

  

	9.3	 Where any Test Materials relevant to the Services are imported for the purposes of the Services under the terms
of this Agreement or a Work Order, import duty, import VAT or other excise duties may be incurred. Where an irrevocable duty is incurred, Covance shall charge the duty onto the Sponsor as a pass through cost. Covance and the Sponsor shall work
together such that irrevocable costs are minimized. 

  

	10	 CHANGE ORDER 

  

	10.1	 If any of the Assumptions: (i) are not complied with by the Sponsor; or (ii) are invalid or
incorrect; or (iii) if the Sponsor requests a change or an extension to the Services; or (iv) if any changes to the Protocol/Scientific Plan arise either at the request of the Sponsor or as a result of scientific obstacles identified
during the provision of the Services (each a Deviation) then the Services, Budget and timelines as specified in the corresponding Work Order shall be modified in accordance with the terms of this Section 10. 

  

			
	Page 10 of 60

	10.2	 In addition, a Deviation may arise if the Services are Delayed for (i) a Force Majeure Event;
(ii) circumstances not attributable to Covance; or (iii) events outside Covance’s reasonable control, including the following: 

(a) failure of the Sponsor to deliver the Sponsor Information in due time; or 

(b) amendments to previously agreed upon Protocol/Scientific Plans, procedures or documents required for the Services at the request of the
Sponsor; or 
 (c) significant delays in pre-study meetings or in other tasks to be performed by
Covance caused by the Sponsor; or 
 (d) Delays in obtaining or subsequent withdrawal of regulatory or ethical review approvals concerning
the Services; or 
 (e) death, incapacity or disability of any third party Investigator or other research specialist to continue their
services in connection with the Services; or 
 (f) unforeseen changes in the relevant medical practice or Regulatory Requirements; or 

(g) if applicable, either a higher ratio of drop-outs among Study subjects or a lower enrollment rate than expected and agreed by Covance and
the Sponsor under the applicable Work Order. 
  

	10.3	 The Parties shall negotiate, in good faith, to agree, in writing, to a change order setting forth the revised
terms for the respective Work Order (a Change Order) as described below. 

  

	10.4	 Covance shall provide the Sponsor with a written estimate of the consequences arising from a Deviation. The
estimate shall be provided to the Sponsor on a Change Order form in the form of Exhibit C or other such mutually agreed upon form by the Parties documenting a Deviation. The Sponsor shall forward to Covance an executed and approved Change Order or
other such mutually agreed upon form and, upon receipt thereof, Covance shall implement the Deviation. 

  

	10.5	 To the extent reasonably practicable, Covance shall continue to provide the Services pending approval of the
Change Order by the Sponsor. Covance shall not be obligated to implement all or any part of the changes without an agreement in writing signed by both Parties. In the event that the Parties cannot agree on such changes, Covance shall not be obliged
to provide non-contracted Services to the Sponsor under the relevant Work Order. In the event the Parties agree on such changes and Covance continues to provide services before the execution of the Change
Order, Covance shall invoice the Sponsor for Services rendered. 

  

	11	 SPONSOR VISITS 

 

	11.1	 Sponsor or its representative (which shall not be a competitor of Covance and which shall be required to be
bound by confidentiality and non-use obligations substantially similar to those contained herein) may visit Covance’s premises where Services are being performed at reasonable times, on reasonable notice
and with reasonable frequency during normal business hours to observe the progress of Services. Covance and Sponsor shall cooperate in scheduling such visits. 

  

			
	Page 11 of 60

	11.2	 Sponsor acknowledges that Sponsor’s representatives granted access to Covance facilities during any such
visits may have access to confidential and proprietary information of Covance and its clients. Sponsor agrees that all such confidential and proprietary information of Covance obtained or observed by the Sponsor or its representatives during such
visits shall remain the sole property of Covance, other third parties or the Sponsor (as applicable). Sponsor agrees that it and its representatives shall treat such information as Confidential Information in accordance with Section 14.

  

	12	 REGULATORY INSPECTIONS AND AUDITS 

 

	12.1	 Except as otherwise provided in the additional terms and conditions of each Company Affiliate that apply to the
services provided by a Company Affiliate (and any Work Orders thereunder) under Exhibit A, the terms of this section shall apply to Services provided under this Agreement and any applicable Work Order. 

 

	12.2	 Covance shall during and up to two (2) years after the term of the Agreement, permit the Sponsor or its
representatives (which shall not be a competitor of Covance) at reasonable times and on reasonable notice to: (a) audit and examine Covance’s principal facilities, operations and quality systems and documentation that are used or that are
intended to be used in the performance of the Services or a Study; and (b) audit and copy the Results, regardless of location. The provisions of this Section shall also apply to Study sites managed by Covance. 

 

	12.3	 In the event that a Party receives a notice from a Regulatory Authority which directly relates to the Services
or a Study, and where possible and permitted by the Regulatory Authority, the Party receiving such notice shall promptly forward to the other Party a copy of such notice (or extract thereof). Each Party shall cooperate with the other in responding
to such notice especially before referring to the other Party in any regulatory correspondence or disclosing any Confidential Information to a Regulatory Authority. However, each Party acknowledges that it may not direct the manner in which the
other Party fulfils its obligations to permit inspection by Regulatory Authorities. 

  

	12.4	 Covance shall cooperate with any inspection or audit by a Regulatory Authority and shall, except where
prohibited by the Regulatory Authority, notify the Sponsor promptly of any request by a Regulatory Authority to conduct such audit or inspection relating to the Services that Covance is providing under this Agreement. 

 

	12.5	 Where possible and permitted by the Regulatory Authority and except where the Sponsor would be exposed to
Confidential Information regarding other sponsor’s development activities, Covance shall use its reasonable efforts to allow the Sponsor or its representatives to be present during any such inspection. Where possible and if acceptable to the
inspecting Regulatory Authority, the Sponsor may attend the inspection and the daily summaries/close-out meetings to discuss topics related to any Studies where the Sponsor is the sponsor.

  

	12.6	 Any request by the Sponsor for Covance to provide assistance with an audit beyond those required to confirm
that Covance is in compliance with its obligations under this Agreement and any relevant Work Orders shall be considered a separate service for which additional fees shall apply. Covance shall seek the Sponsor’s written approval to pay any
related fees before performing any additional audit services. 

  

	13	 POTENTIAL FRAUD, MISCONDUCT AND SERIOUS BREACH 

 

	13.1	 Potential Serious Breaches shall be initially assessed through Covance’s issue escalation process. When a
significant and potential regulatory reporting requirement applicable to the issue is confirmed by Covance, Covance shall promptly notify the Sponsor in writing. 

  

			
	Page 12 of 60

	13.2	 Upon notification from Covance of a potential Serious Breach, the Sponsor shall review the issue and the
Parties shall try to agree which Party shall have the responsibility for informing the relevant Regulatory Authority. Notwithstanding the foregoing, Covance reserves the right to act in accordance with its ethical responsibilities and legal
obligations. Covance shall provide a copy of any such correspondence to the Sponsor. 

  

	14	 CONFIDENTIAL INFORMATION 

 

	14.1	 Each Party agrees that all Confidential Information of the Disclosing Party is and shall be the sole property
of the Disclosing Party. Without prejudice to any Covance Property, all test information, Results, data and records developed by Covance specifically as a result of performing the Services and related to the Test Materials or Sponsor Information
shall be the Confidential Information of the Sponsor. 

  

	14.2	 The Receiving Party shall: 

(a) hold the Confidential Information of the Disclosing Party in confidence and in a manner consistent with the way in which it maintains the
confidentiality of its own proprietary information, being at least a reasonable standard of care; and 
 (b) disclose the Confidential
Information of the Disclosing Party only on a ‘need to know’ basis, to its employees, officers, directors, representatives and third party Investigators. 
  

	14.3	 The Receiving Party agrees that, except with the Disclosing Party’s written approval or as necessary to
fulfil its obligations under this Agreement or a Work Order and agreed by the Disclosing Party, it shall not use or disclose to any other third party any of the Confidential Information of the Disclosing Party. 

 

	14.4	 The obligations of non-use and
non-disclosure shall not apply to Confidential Information of the Disclosing Party that the Receiving Party can show: 

(a) was, or becomes, publicly known through no fault of the Receiving Party; 

(b) was lawfully obtained from a third party without restriction as to its use or disclosure; 

(c) was already in the possession of the Receiving Party prior to disclosure; or 

(d) was independently developed by the Receiving Party without the benefit of the Confidential Information of the Disclosing Party. 

 

	14.5	 The Receiving Party shall be entitled to disclose Confidential Information of the Disclosing Party to the
extent required by any law, rule, regulation, order, decree or subpoena, including the public filing of this Agreement, the Exhibits and the Work Orders with the Securities Exchange Commission, except that the Receiving Party shall, unless
restricted by law or where not practicable, promptly notify the Disclosing Party of such requirement prior to the disclosure and shall cooperate with the Disclosing Party to seek to oppose, minimize or obtain the confidential treatment of the
required disclosure. 

  

	14.6	 The obligations in this Section 14 shall remain in full force and effect for a period of seven
(7) years following disclosure of the relevant Confidential Information except with respect to Confidential Information which is considered a trade secret under applicable laws, which shall remain confidential as long as such
Confidential Information retains its status as a trade secret.  

  

			
	Page 13 of 60

	15	 INTELLECTUAL PROPERTY RIGHTS 

 

	15.1	 All Background IP is and shall remain the exclusive property of the Party owning it and except as expressly
provided in this Agreement, no Party shall acquire any rights in or to the Background IP of the other Party. 

  

	15.2	 The Sponsor acknowledges that Covance owns or is licensed to use Covance Property. The Parties agree that any
improvement, enhancement or modification made, conceived or developed by or for Covance to any Covance Property in the performance of the Services which is not developed as a result of the Services or a Work Order, or based on the Sponsor’s
Confidential Information for the performance of the Services shall be deemed Covance Property and shall vest absolutely and exclusively in Covance. In addition, Covance shall be entitled to use and exploit any skills, techniques or know-how acquired, developed or used in the course of the Services and a Work Order and not related to the Test Materials or Sponsor Information. 

 

	15.3	 Strategic insight and proposed project design and scope provided in any quotation by Covance is and shall
remain the property of Covance and may be used by the Sponsor only to assess whether it wishes to pursue such work with Covance. 

  

	15.4	 Without prejudice to Sections 15.1 and 15.2, and as to any Deliverable upon receipt by Covance of payment in
full of all amounts due and payable under a Work Order for such Deliverables, the Sponsor shall have title to the Deliverables and all intellectual property rights therein. Covance agrees to assign such rights to the Sponsor except that one
(1) copy of any final report may be retained by Covance for regulatory or legal compliance purposes. Notwithstanding the foregoing, the Sponsor hereby grants Covance a non-exclusive, perpetual,
irrevocable, royalty-free licence to aggregate and use, for internal quality, standards and performance measurement, instrument calibration and method validation purposes, any System Data produced by or for Covance as part of the Services with other
System Data owned or licenced by Covance, provided that Covance shall not identify such data as belonging to the Sponsor. 

  

	15.5	 Covance shall disclose to the Sponsor (or its nominee) all Inventions and, except in relation to Covance
Property and at the Sponsor’s request (provided such request is made within one (1) year of disclosure), Covance shall assign to the Sponsor or its nominee (as appropriate) the rights to such an Invention. At the Sponsor’s request and
expense, Covance shall do all reasonably necessary acts to vest the Invention in the name of the Sponsor or its nominee. 

  

	15.6	 Except for any Covance Property owned by a third party, if any Covance Property is incorporated or included in
any Deliverable (Incorporated Covance IP), Covance grants the Sponsor a royalty-free, perpetual, non-exclusive, non-transferable, non-sublicensable,
world-wide license to use any Incorporated Covance IP for the sole purposes of and to the extent reasonably necessary to incorporate or explain any Deliverables (without modification) and for obtaining regulatory approvals in connection with such
Deliverables. 

  

	16	 RECORD RETENTION 

Except as otherwise directed by the Sponsor, Covance shall retain all Results relating to a Study or the Services during the term of the
applicable Work Order. Upon completion or earlier termination of a Study or the Services or earlier if requested by the Sponsor, the Results for the applicable Study or the Services shall be delivered to the Sponsor. Covance shall not be required to
return ancillary documents related to the Study Records (including invoices and other similar records). Notwithstanding the foregoing, Covance shall be permitted to retain archival copies of such records if and to the extent that such Results are
required to be stored or maintained by Covance pursuant to Regulatory Requirements or other requirements. 

  

			
	Page 14 of 60

	17	 LICENSED TECHNOLOGY 

 

	17.1	 If any software including third party software (Software) is made available by Covance and is used or
disclosed to the Sponsor in connection with the Services, save as permitted by law, the Sponsor agrees not to: (a) modify, copy or create derivative works based on the Software; (b) reverse engineer, disassemble or decompile the Software
in any manner; (c) resell, sublicense, lease, or time-share the Software; (d) publish the results of any benchmark tests run on the Software; and (e) use the Software to build a competitive product or service or for the purpose of
copying its features or user interface. 

  

	17.2	 To the extent that any Confidential Information includes Software that is licensed to Covance from third
parties (such as, for example, licensors of electronic data capture software), such third parties shall be third-party beneficiaries of this Section 17 with the right to enforce the limitations herein, but shall not otherwise have any rights
under this Agreement. 

  

	18	 REMEDIES AND LIMIT OF LIABILITY 

 

	18.1	 Except as otherwise provided in the additional terms and conditions of each Company Affiliate that apply to the
services provided by a Company Affiliate (and any Work Orders thereunder) under Exhibit A, the terms of this section shall apply to Services provided under this Agreement and any applicable Work Order. 

 

	18.2	 Covance’s total liability to the Sponsor as to any Work Order or under this Agreement with respect to such
Work Order, whether in contract, tort (including negligence) or otherwise shall in no circumstances exceed [*]. 

  

	18.3	 Nothing in this Agreement excludes or limits the liability of either Party where liability cannot be excluded
or restricted as a matter of law. 

  

	18.4	 In no event shall Covance be liable to the Sponsor for any Loss arising under or in connection with this
Agreement and the Work Order in respect of any: (a) loss of profit, opportunity, business, saving or goodwill (in each case whether direct or indirect); or (b) any indirect, consequential punitive, exemplary or special damages or losses.

  

	18.5	 Covance shall not be liable for any failure, error or Delay in performing the Services if such failure, error
or Delay is caused by the Sponsor or is a result of an express instruction from the Sponsor or a change in Sponsor Information. 

  

	18.6	 Except for the representations, warranties, covenants and other obligations set out in this Agreement and Work
Order, all warranties, conditions, terms and undertakings, express or implied, whether by statute, common law, custom, trade usage, course of dealings or otherwise (including as to quality, merchantability, performance or fitness or
suitability for purpose) in respect of any services to be provided by Covance are excluded to the fullest extent permitted by law. 

  

	19	 INDEMNITIES 

  

	19.1	 Except as otherwise provided in the additional terms and conditions of each Company Affiliate that apply to the
services provided by a Company Affiliate (and any Work Orders thereunder) under Exhibit A, the terms of this section shall apply to Services provided under this Agreement and any applicable Work Order. 

  

			
	Page 15 of 60

	19.2	 Covance shall indemnify, defend and hold harmless the Sponsor and its respective officers, directors, employees
and agents (the Sponsor Group) from any Loss resulting from and against any Claim arising from or related to: 

(a) a violation of any applicable law, rule or regulation; 

(b) a breach of this Agreement or Work Order by Covance; or 

(c) the personal injury to a Study participant or personal injury to any employee within the Sponsor Group or property damage arising or
occurring during the conduct of the Services 
  

	19.3	 that arises as a result of Covance’s negligence or intentional misconduct of Covance in performing the
Services provided that if such Losses or Claims arise in whole, or in part, from the Sponsor’s Group’s negligence or intentional misconduct, then the amount of such Losses that Covance shall be responsible for pursuant to this
Section 19.2 shall be reduced by an amount in proportion to the percentage of the Sponsor’s Group’s responsibilities for such Losses as determined by a court of competent jurisdiction in a final and
non-appealable decision or in a binding settlement between the Parties. The Sponsor shall indemnify, defend and hold harmless Covance and its Affiliates and their respective officers, directors, employees and
agents from any Loss resulting from and against any Claim arising from or related to: 

 (a) personal injury to a
participant in a Study during the conduct of or in connection with the Services; 
 (b) the harmful or otherwise unsafe effect of the Test
Materials including a Claim based upon the Sponsor’s or any other person’s use, consumption, sale, distribution or marketing of such Test Materials; 

(c) a violation of any applicable law, rule, regulation or this Agreement or Work Order by the Sponsor; 

(d) the Sponsor’s use of the Results or Deliverables or its use or marketing of any Test Materials tested by Covance; 

(e) the negligence or intentional misconduct of the Sponsor in connection with the Test Materials, this Agreement, a Work Order or a
Protocol/Scientific Plan related to the Services; or 
 (f) the infringement, unlawful disclosure or misappropriation of copyright, patent,
trade secret, or other intellectual property of a third party by reason of Covance’s use of the Sponsor Information or Test Materials in accordance with the terms of this Agreement, 

provided that if such Losses or Claims arise in whole, or in part, from Covance’s negligence or intentional misconduct, then the
amount of such Losses that the Sponsor shall be responsible for pursuant to this Section 19.3 shall be reduced by an amount in proportion to the percentage of Covance’s responsibilities for such Losses as determined by a court of competent
jurisdiction in a final and non-appealable decision or in a binding settlement between the Parties. 

  

			
	Page 16 of 60

	19.4	 Sponsor shall indemnify, defend, and hold harmless any third-party electronic data capture, electrocardiogram,
drug supply/depot and interactive voice-response/interactive response technology Vendors approved by the Sponsor and under contract with Covance to provide any Services (Ancillary Service Provider) from any Claims to the extent the
Claims arise from or relate to: 

 (a) the harmful or otherwise unsafe effect of the Test Materials, including a Claim
based upon the Sponsor’s or any other person’s use, consumption, sale, distribution or marketing of such Test Material, or 
 (b)
the negligence or intentional misconduct of the Sponsor in connection with the Test Materials, this Agreement, a Work Order or a Protocol/Scientific Plan related to the Services, 

provided that if such Claims arise in whole or in part from such Ancillary Service Provider’s: (i) negligence or intentional
misconduct; (ii) violation of applicable law, rule or regulation; (iii) breach of its contractual obligations to the Sponsor or Covance; or (iv) any alleged or actual intellectual property infringement in the performance of the
Services, then the amount of such Claims that the Sponsor shall be responsible for pursuance to this Section 19.4 shall be reduced in proportion to the percentage of such Ancillary Service Provider’s responsibilities for such Claims as
determined by a court of competent jurisdiction in a final and non-appealable decision or in a binding settlement between the parties. An Ancillary Service Provider shall be an intended third-party beneficiary
of the indemnification provided in this Section 19.4, but shall not otherwise have any rights under this Agreement. 
  

	19.5	 The Party entitled to indemnification under this Section 19 (the Indemnified Party) shall promptly
give written notice to the other Party (Indemnifying Party) of a Claim or other circumstances likely to give rise to a request for indemnification after the Indemnified Party becomes aware of the same. The Indemnifying Party shall be afforded
the opportunity to undertake the defense of, and to settle by compromise, or otherwise, any Claim for which indemnification is available under this Section 19. 

 

	19.6	 If the Indemnifying Party assumes the defense of any Claim, the Indemnified Party may participate in such
defense with legal counsel of its selection and at its expense. If the Indemnifying Party, prior to the expiration of thirty (30) days after receipt of written notice of the Claim by the Indemnified Party under this Section 19.5, has not
assumed the defense thereof, the Indemnified Party may thereupon undertake the defense on behalf of, at the risk and expense of, the Indemnifying Party with all reasonable costs and expenses of such defense to be paid by the Indemnifying Party.

  

	19.7	 In the event that the Indemnified Party assumes the defense of any Claim, no compromise or settlement of any
such claim shall be made without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld or delayed. 

  

	19.8	 To the extent that Covance has to indemnify the Sponsor Group for Financial Interest Claims, Covance’s
indemnification obligations for such claims shall not exceed and shall be subject to the limitation of liability terms in Section 18. 

  

	19.9	 Nothing in this Section 19 shall restrict or limit an Indemnified Party’s general obligation at law
to mitigate a loss it may suffer or incur as a result of an event that may give rise to a Claim under this Section. 

  

	20	 CARRIER LIABILITY 

 

	20.1	 In the event that either: (i) the Sponsor delivers, ships or mails (Transports) substances,
samples, material or documents (Packages) to Covance; (ii) the Sponsor requests that Covance Transports Packages; or (iii) Covance Transports Packages as part of the Services to the Sponsor, a Sponsor Affiliate, another Covance
entity or a third party, then the expense and risk of damage (insurance) and loss of the Packages for such Transport together with any expenses 

  

			
	Page 17 of 60

	 	
required under applicable Regulatory Requirements shall be borne by the Sponsor; provided however if such damage or loss of the Packages arises as a direct result of Covance’s negligence or
intentional misconduct in the manner in which the Package was prepared for shipment, or the manner and time in which it was consigned for shipment, or the way in which the Package was transported by Covance, then Covance shall bear such damage or
loss in proportion to the percentage of Covance’s responsibility for such damage or loss. 

  

	20.2	 Subject to the foregoing, Covance shall have no liability whatsoever for any loss or damage to the Packages or
delay, non-delivery or non-collection of the Packages caused by the acts or omissions of any third party delivery services or carrier (Carrier). Notwithstanding
the foregoing, to the extent permitted by law, Covance shall have the benefit of any right or remedy permitted under international or domestic law and any sums recovered by Covance from a Carrier as a consequence of a loss incurred by the Sponsor
due to the Carrier’s involvement with the Services shall be paid to the Sponsor. For the avoidance of doubt, a Carrier is not considered a Subcontractor for the purposes of this Agreement. 

 

	20.3	 Unless otherwise agreed in writing between the Parties, any physical Deliverables to be shipped to the Sponsor
shall be to the delivery address specified in the Work Order. Upon delivery of any physical Deliverables, the Sponsor shall be responsible for carefully examining such Deliverables. The Sponsor shall be deemed to have accepted such Deliverables if
Covance has not been notified by the Sponsor within thirty (30) business days of delivery of any defect in such Deliverables. 

  

	21	 TERMINATION 

  

	21.1	 On termination of this Agreement, howsoever arising, each Work Order then in force at the date of such
termination shall nevertheless continue in full force and effect for the remainder of the term of such Work Order, unless expressly terminated in accordance with this Section 21. Termination of any Work Order shall not affect any other Work
Order or this Agreement. 

  

	21.2	 A Party may terminate a Work Order prior to completion of the applicable Services at any time for any reason
upon ninety (90) days written notice to the other Party, except when the reason for termination is the safety of Study participants, whereupon it may be terminated immediately. Covance shall use reasonable efforts to conclude or transfer the
Study as expeditiously as practicable and in accordance with all applicable Regulatory Requirements. Covance and the Sponsor shall cooperate with each other during such termination to safeguard patient safety, continuity of patient treatment and to
comply with all applicable Regulatory Requirements. 

  

	21.3	 To the extent permitted by law, either Party may terminate this Agreement and all relevant Work Orders with
immediate effect by notice in writing to the other Party if: 

 (a) the other Party commits a material breach of any term
of this Agreement which breach is irremediable or (if such breach is remediable) fails to remedy that breach within a period of forty-five (45) days after being notified in writing to do so; or 

(b) the other Party repeatedly breaches any of the terms of this Agreement in such a manner as to reasonably justify the opinion that its
conduct is inconsistent with it having the intention or ability to give effect to the terms of this Agreement; or 
 (c) the other Party
suspends, or threatens to suspend, payment of its debts or is unable to pay its debts as they fall due or admits inability to pay its debts or is deemed unable to pay its debts; or the other Party suspends, or threatens to suspend, or ceases or
threatens to cease to carry on, all or substantially the whole of its business; or 

  

			
	Page 18 of 60

 (d) the other Party presents a petition or has a petition presented for its winding-up or has a receiver or an administrative receiver appointed of all or any part of its assets or undertaking or if a notice of intention to appoint an administrator is served in respect of it or calls a
meeting of, or enters into any composition or arrangement with, its creditors; or 
 (e) the financial position of either Party deteriorates
to such an extent that in the other Party’s reasonable opinion a Party’s capability to adequately fulfil its obligations under the Agreement has been placed in jeopardy; or 

(f) any event occurs, or proceeding is taken, in any jurisdiction to which it is subject that has an effect equivalent or similar to any of the
events mentioned above. 
  

	21.4	 Termination of this Agreement, or Work Order, shall not relieve either Party of their obligations to the other
in respect of: 

  

	 	(a)	 maintaining the confidentiality of the Confidential Information; 

 

	 	(b)	 assignment of Inventions and assistance with respect thereto; 

 

	 	(c)	 obtaining consents for the use of names; 

 

	 	(d)	 indemnification; 

  

	 	(e)	 limitation of liability; 

 

	 	(f)	 compensation for the Services performed; 

 

	 	(g)	 retention of records; 

 

	 	(h)	 reimbursement and payment for legal proceedings; 

 

	 	(i)	 non-solicitation of employees. 

The provisions of this Section together with and any other section which is necessary for the interpretation or enforcement of this Agreement
shall survive the expiry or termination of this Agreement howsoever arising. 
  

	22	 CONSEQUENCES OF DELAY, CANCELLATION OR TERMINATION 

 

	22.1	 Except as otherwise provided in the additional terms and conditions of each Company Affiliate that apply to the
services provided by a Company Affiliate (and any Work Orders thereunder) under Exhibit A, the terms of this section shall apply to Services provided under this Agreement and any applicable Work Order. 

 

	22.2	 If the scheduled start up of the Services are Delayed due to: (i) delay by the Sponsor (e.g. due to non-delivery of Test Materials or any Sponsor Information required to begin or perform the Services); (ii) delay in any approval by a Regulatory Authority or IEC/IRB; (iii) at the request of the Sponsor; or
(iv) any other reason outside the reasonable control of Covance, Covance shall be entitled to full payment for: 

 (a)
all work properly performed by Covance for the Services up to the notification of Delay; 
 (b) all pass through costs related directly to
the Services and incurred up to the notification of Delay; 
 (c) all other non-cancellable actual, non-refundable or irrevocably incurred expenses and financial obligations that Covance has incurred or undertaken in support of the Delayed Services or as a consequence of the Delay (e.g. the cost of staff members
allocated to a Study which is Delayed who are not re-assigned to other work during the period of the Delay and regulatory expenses); and 

  

			
	Page 19 of 60

 (d) any additional fees listed in the relevant Exhibit A or Work Order as a consequence of the
Delay. 
  

	22.3	 In the event that the Services are cancelled or terminated in accordance with Sections 21.2 or 21.3, Covance
shall be entitled to full payment for: 

 (a) all work properly performed by Covance for the Services up to the effective
date of cancellation or termination regardless of the achievement of any milestones used as payment triggers (including any agreed wind down costs); 

(b) all pass through costs related directly to the Services and incurred up to the effective date of cancellation or termination; 

(c) all other non-cancellable actual, non-refundable or
irrevocably incurred expenses and financial obligations that Covance has incurred or undertaken on the Sponsor’s behalf up to the effective date of cancellation or termination; and 

(d) any additional termination for convenience fees listed in the relevant Exhibit A or Work Order. 

 

	23	 INSURANCE 

Each Party shall secure and maintain in full force and effect through the performance of the Services the necessary insurance coverage in
amounts appropriate to the conduct of its business. Certificates evidencing such insurance shall be made available for examination upon written request by the Sponsor or Covance. The additional insurance requirements that may apply to any specific
Services are detailed in the relevant Exhibit A. 
  

	24	 SAMPLE RETENTION 

 

	24.1	 Subject to Section 24.2 and any provisions in Exhibit A, all Samples associated with the Services shall be
retained, returned to the Sponsor or disposed of (including destruction) in accordance with the Work Order, Protocol/Scientific Plan or the Sponsor’s reasonable written instructions and applicable Regulatory Requirements. Where no provision is
made in the Work Order or Protocol/Scientific Plan, the Sponsor shall be contacted to determine whether the Samples should be destroyed, returned to the Sponsor or retained by Covance subject to agreement of the Parties on the time period and fees
payable for retention. 

  

	24.2	 Regulatory samples obtained from drug substance or drug product shall be retained and disposed of in accordance
with the Protocol/Scientific Plan. Samples obtained from clinical trials and HBS shall be retained and disposed of in accordance with the provisions of Section 25 of this Agreement. 

 

	25	 HUMAN BIOLOGICAL SAMPLES 

 

	25.1	 Where Covance is performing Services that includes monitoring activities of a Study on behalf of the Sponsor at
investigative sites, Covance shall: 

 (a) verify that the HBS Donor has given Informed Consent; 

(b) confirm that any HBS and associated data are managed in full compliance with any and all applicable national laws, regulations, or codes of
practice (including any submissions, approvals and registrations to any applicable Regulatory Authority) relating to the Use of HBS providing protection for human subjects in the country of origin; 

  

			
	Page 20 of 60

 (c) use its reasonable efforts to ensure that any HBS shall be
de-identified or ‘coded’ according to applicable Regulatory Requirements to protect the identity and confidentiality of the HBS Donor; and 

(d) in the event of a withdrawal of or a material variation to the Informed Consent, promptly notify all relevant parties of such withdrawal or
variation.
  

	25.2	 In all other circumstances, where the Sponsor or third parties for which the Sponsor is responsible supply HBS
to Covance in connection with the Services, the Sponsor represents and warrants that: 

 (a) all HBS supplied in connection
with the Services under this Agreement and any relevant Work Order are or have been procured and supplied to Covance ethically in full compliance with any and all applicable national laws, regulations, or codes of practice (including any
submissions, approvals and registrations to any applicable Regulatory Authority) relating to the Use of HBS providing protection for human subjects in the country of origin; 

(b) the HBS Donor has given Informed Consent; 

(c) all HBS shall be de-identified or ‘coded’ according to applicable Regulatory Requirements
to protect the identity and confidentiality of the HBS Donor and shall be supplied to Covance without any information or data that could allow Covance to personally identify the HBS Donor under applicable Data Protection Laws and other applicable
Regulatory Requirements; 
 (d) all HBS supplied to Covance (i) may be Used for the Services; (ii) may be used to provide data in
support of commercial product development by Sponsor; and (iii) were procured without inappropriate financial benefit to the HBS Donor; and 

(e) in the event of a withdrawal of, or a material variation to the Informed Consent (including any material changes that may affect the
Services), it shall promptly notify Covance and any other relevant parties of such changes or withdrawal. 
  

	25.3	 The Sponsor shall: (a) upon request, provide a copy of the relevant Informed Consent template; and
(b) upon request, provide a copy of the relevant documents certifying that the HBS provided to Covance has completed the necessary submissions, approvals and registrations required to be made to any applicable Regulatory Authority. The Sponsor
agrees that full date of birth shall only be collected if medically relevant to the Services (unless legally restricted in the country of operation). 

  

	25.4	 Covance agrees to use the HBS in accordance with all applicable laws, regulations and codes of practice.
Covance shall not use the HBS, even on a de-identified or coded basis for any purpose other than in accordance with the signed Informed Consent form. 

 

	25.5	 Upon the Sponsor’s request, Covance shall retain, return or dispose of all HBS in accordance with the
Informed Consent, the Sponsor’s reasonable instructions or any other specific requirements under applicable national law. 

  

	25.6	 The Sponsor acknowledges that where Covance enters into a material transfer agreement (MTA) with the
provider of any HBS, Covance shall act in accordance with the terms of the MTA and the disposition of the relevant HBS shall be as prescribed in the MTA. In the event of a conflict between the terms of the MTA, this Agreement, any Work Order and any
instructions provided by the Sponsor, the terms of the MTA shall prevail. 

  

			
	Page 21 of 60

	26	 DATA PROTECTION 

 

	26.1	 Where Covance processes any Personal Data on behalf of the Sponsor, Covance shall process such Personal Data in
accordance with all applicable Data Protection Laws in the territories in which the Services are performed (Protected Data). 

  

	26.2	 If Covance processes any Protected Data on behalf of the Sponsor, Covance and the Sponsor each agree and
acknowledge that the Sponsor shall be the data controller and Covance shall be the data processor with respect to the processing of such Protected Data. Covance shall only process such Protected Data on behalf and upon the reasonable instructions of
the Sponsor for purposes notified to it by the Sponsor for which consent from the relevant data subjects has been obtained in accordance with all applicable Regulatory Requirements. Covance shall follow such procedures, policies and reasonable
instructions as may be agreed by the Parties from time to time. 

  

	26.3	 Covance shall take reasonable technical and organizational measures that are necessary to protect against the
unauthorized or unlawful processing of or the unauthorized or unlawful disclosure of such personal data. Covance shall promptly notify the Sponsor in the event of a security breach involving any personal data which Covance is processing on behalf of
the Sponsor. 

  

	26.4	 The Sponsor warrants that it has complied with any and all notification and information requirements under the
applicable Data Protection Laws. 

  

	27	 SUBCONTRACTORS AND VENDORS 

 

	27.1	 Notwithstanding Section 33.2, certain tasks other than data processing tasks specified in the Work Order
or Protocol/Scientific Plan may be subcontracted by Covance to its Affiliates or Subcontractors. Covance shall be responsible for the performance of Subcontractors contracted by Covance for services within the scope of this Agreement.

  

	27.2	 Covance shall diligently identify, vet, engage, manage and monitor the performance of Vendors, but shall not
otherwise be responsible for performance by Vendors that are not Subcontractors. The liability of Covance to the Sponsor with respect to Vendors shall be limited to the extent Covance defaults in the performance of its obligations under this
Agreement or a Work Order. At the reasonable request of Sponsor Covance shall pursue on Sponsor’s behalf and at Sponsor’s expense any claims that Sponsor or Covance may have against Vendors as a consequence of a loss incurred by Sponsor as
a result of any error or service failure on the part of such Vendors in connection with this Agreement or any Services under a Work Order, and Covance shall pay over to Sponsor any amounts that Covance may recover from such Vendors on account
thereof. 

  

	27.3	 For the avoidance of doubt, the Parties acknowledge and agree that third party Investigators shall not be
considered Subcontractors of Covance. All third party Investigators shall exercise their own independent medical judgement and shall be considered independent contractors and shall not be deemed employees, subcontractors or agents of Covance.
Covance’s responsibilities with respect to third party Investigators shall be limited to those responsibilities specifically set forth in the Agreement and the applicable Work Order. 

  

			
	Page 22 of 60

	28	 FORCE MAJEURE 

 

	28.1	 No Party shall be in breach of this Agreement or Work Order nor liable for delay in performing, or failure to
perform, any of its obligations under this Agreement or Work Order as appropriate, if such delay or failure results from a Force Majeure Event. In such circumstances, any time specified for completion of performance in the Work Order or
Protocol/Scientific Plan falling due during or subsequent to the occurrence of a Force Majeure Event shall be automatically extended for a period of time equal to such event. The Party whose performance is delayed by Force Majeure shall use
commercially reasonable efforts to mitigate any delays cause by the Force Majeure Event. Covance shall promptly notify the Sponsor if, by reason of a Force Majeure Event, Covance is unable to meet any critical timelines or critical deliverables
specified in any Work Order. 

  

	28.2	 Should any part of the Services be rendered invalid as a result of a Force Majeure Event, Covance shall, upon
written request from the Sponsor, and at the Sponsor’s sole cost and expense, repeat the affected part of the Services. 

  

	29	 NOTICES 

  

	29.1	 Except for the purposes of any legal notice or proceedings, which shall not include email or fax, all
communications and notices required under this Agreement shall be in writing and deemed to be given if delivered personally, or mailed by overnight delivery or first class mail, postage prepaid, to the addresses set forth below, or via electronic
mail or fax with hard copy confirmation, or to such other addresses as the Parties from time to time specify in writing. 

  

	29.2	 Notices shall be treated as having been given upon delivery if delivered by hand or by commercial courier at
the time of signature of receipt; if sent by prepaid first class mail or recorded delivery three (3) days from the date of posting; and if by airmail seven (7) days from the date of posting. 

 

	29.3	 Notice shall be given to the parties at the addresses listed below or at such other place as a Party shall
nominate: 

  

	 	(a)	 If to Sponsor to: 

Galectin Therapeutics, Inc. 
 4960
Peachtree Industrial Boulevard, Suite 240 
 Norcross, Georgia 30071, Unites States 

Attention: Chief Executive Officer 
  

	 	(b)	 If to Covance, the address set forth in the Notice Section of any relevant Exhibit A, with a copy to Covance
Inc. at the following address: 

 Covance Inc. 

3147 S. 17th Street, Suite 300 Wilmington, NC 28412 

United States 
 Attention: General
Counsel 

  

			
	Page 23 of 60

	30	 PUBLICITY AND PUBLICATION 

Neither Party shall (a) use the name, trademark or the name of any representative of the other, or the existence of this Agreement for any
promotional or advertising purposes, or any other publication, without the prior written consent of the other Party; or (b) state or imply that the other Party endorses or approves any service, material, product or compound of the other Party
without the prior written consent of the other Party. Such restrictions shall not apply to internal communications and publications to a Party’s Affiliates or to communications or publications that are required for Sponsor to comply with US
Securities laws. 
  

	31	 PERSONNEL 

  

	31.1	 Except as provided in Section 31.2, neither Party shall solicit or otherwise encourage any personnel or
employees of the other Party with whom it has contact pursuant to this Agreement to seek employment with a Party throughout the course of the Agreement and for a period of twelve (12) months thereafter. 

 

	31.2	 Section 31.1 shall not apply in the event: (i) the potential recruiting Party has consulted with the
other Party and obtained permission to solicit such employee; (ii) an employee of a Party seeks employment with the other Party in response to an unsolicited response to a general advertisement or recruiting effort not directed at such employee
or Party; or (iii) an employee of either Party who is terminated or otherwise released from employment by Party or its Affiliates. 

  

	31.3	 The Services with respect to each Work Order shall be performed by Covance under the direction of the person
identified as the operational lead in the applicable Work Order or other Services relevant documentation. Where reasonably practicable, Covance shall retain the operational lead for a Study in place during the term of the applicable Work Order
unless Sponsor requests a change in writing. In the event that a change in the operational lead occurs, then Covance will discuss and make available to Sponsor qualified candidates to fill the role of the operational lead and will consult with the
Sponsor about such replacement. After such consultation and review, Sponsor’s acceptance and approval of the replacement operational lead shall not be unreasonably withheld or delayed. 

 

	32	 COMPLIANCE 

  

	32.1	 Debarment. Covance represents and warrants that to its knowledge it does not use and shall not use in
any capacity the services of any person debarred under subsections §306(A) or §306(B) of the U.S. Generic Drug Enforcement Act 1992, disqualified as a testing facility under 21 CFR Part 58 Subpart K. or disqualified, restricted or having
made assurances as a clinical investigator under 21 CFR §312.70 or otherwise debarred, restricted or disqualified under the corresponding laws of an applicable jurisdiction in connection with any of the Services performed under this Agreement.
Covance shall promptly disclose in writing to the Sponsor if it becomes aware that any: (a) person who is performing the Services is debarred, disqualified or restricted; or (b) action, suit, claim, investigation or legal or administrative
proceeding is pending relating to the debarment, disqualification, restriction of Covance or any person performing Services under this Agreement. 

  

	32.2	 Anti-Bribery. Each Party agrees that it has not and shall not, either directly or indirectly, engage in
the following conduct: bribery or offer, promise, authorize to pay, or make any improper payment of any monies or financial or other advantage, including cash, loan, gift, travel, entertainment, hospitality, facilitation payment, kickback, political
or philanthropic contribution, anything of value, or any other perceived benefit to improperly obtain or retain a business advantage in violation of any Anti-Corruption Laws and further, each Party agrees that it shall not take any action that would
cause the other Party to be in violation of such Anti-Corruption Laws. 

  

			
	Page 24 of 60

	32.3	 Trade Control. Notwithstanding any other provision of this Agreement to the contrary, each Party shall
comply with, and retain responsibility for its compliance with, all applicable export control laws (e.g., the U.S. Export Administration Regulations) and economic sanctions programs (e.g., economic sanctions maintained by the U.S. Treasury
Department, as well as Specially Designated Nationals and Blocked Persons (SDNs)) relating to its respective business, facilities, and the provision of services to third parties (collectively, Trade Control Laws). It shall be in the
sole discretion of Covance to refrain from being directly or indirectly involved in the provision of goods, software, services and/or technical data that may be prohibited by applicable Trade Control Laws, including sanctions currently in place
against Cuba, Iran, North Korea, Sudan, Syria and SDNs. 

  

	33	 GENERAL 

  

	33.1	 Independent Contractor. It is understood and agreed that Covance shall perform its duties as an
independent contractor and not as an agent, employee, partner or joint venture of the Sponsor. Neither Party shall have the authority to bind or commit the other Party in any manner whatsoever and shall not, at any time, hold itself out to third
parties as having authority to enter into or incur any commitments, expenses, liabilities or obligations of any nature on behalf of the other party except as permitted in this Agreement, a Work Order, or other document expressly providing such
authority. 

  

	33.2	 Assignment. Each Party may transfer or subcontract any or all of its rights and obligations under this
Agreement or a Work Order to its Affiliates. The assigning Party shall continue to remain liable for any accrued obligations under this Agreement or a Work Order prior to such assignment. Notwithstanding the foregoing and except in connection with
an internal reorganization of a Party’s corporate structure or in connection with a merger or sale of substantially all of the assets of a Party, this Agreement shall not be assigned in whole or in part by either Party without the prior written
consent of the other Party, which consent shall not be unreasonably withheld or delayed. 

  

	33.3	 Waiver. A waiver of any term, provision or condition of this Agreement or Work Order shall be effective
only if it is in writing and no waiver, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver or estoppel of any such term, provision or condition or any other term of this Agreement or a Work Order. No
failure or delay by either Party in exercising any right or remedy under this Agreement shall constitute a waiver of such right, nor shall it prevent or restrict its further exercise. The Parties acknowledge and agree that they have not relied upon
any representations made before contract in deciding to enter into this Agreement and the Parties waive all and any right to pursue any claim for misrepresentation except for fraudulent misrepresentation. 

 

	33.4	 Variation. No provision of this Agreement or Work Order may be amended, modified, varied, discharged or
terminated except by the express written agreement signed by an authorized representative of each of the Parties. 

  

	33.5	 Severability. If any court or competent authority finds that any provision of this Agreement (or part of
any provision) is invalid, illegal or unenforceable, that provision or part-provision shall, to the extent required, be deemed to be deleted, and the validity and enforceability of the other provisions of this Agreement shall not be affected. If any
invalid, unenforceable or illegal provision of this Agreement would be valid, enforceable and legal if some part of it were deleted, the provision shall apply with the minimum modification necessary to make it legal, valid and enforceable.

  

			
	Page 25 of 60

	33.6	 Entire Agreement. This MSA together with the Exhibits and Work Order sets forth the entire agreement
between the Parties with respect to the performance of the Services and as such, supersedes all prior and contemporaneous negotiations, agreements, representations, understandings, and commitments with respect thereto and shall take precedence over
all terms, conditions, and provisions on any purchase order or other form of other acknowledgment or order release purporting to address the same subject matter; except that any agreement entered into prior to the Effective Date with respect
to any Services that are being performed before the Effective Date shall remain effective and shall continue to govern such existing Services. 

  

	33.7	 Legal Testimony. If Covance is obliged to provide testimony or records regarding the Services for the
Sponsor in any legal or administrative proceeding other than testimony or records related to any alleged improper performance by Covance of its obligations under this Agreement or a Work Order, then the Sponsor shall reimburse Covance for its out of
pocket costs plus a reasonable hourly fee for the involvement of its employees or representatives in such proceedings equal to the internal fully burdened cost of such employees or representatives. 

 

	33.8	 Third Party Rights. Except as expressly set forth in this Agreement in respect of Covance Affiliates and
Sections 17 and 19.3, nothing in this Agreement is intended to confer any rights, benefits or remedies of any kind whatsoever, and a person who is not a Party to this Agreement shall have no right to enforce any of its terms. 

 

	33.9	 Counterparts. This Agreement may be executed in any number of counterparts, each of which when executed
and delivered shall constitute an original to this Agreement but all of which together shall constitute the same Agreement. 

  

	33.10	 Dispute Resolution. It is the intention of the Parties that in the event disputes should arise over the
interpretation and application of this Agreement, the Parties shall first attempt to settle such disputes by negotiation and consultation between the senior executives of the Sponsor and Covance and other parties familiar with this Agreement, any
Work Order or Protocol/Scientific Plan. To the extent permitted by law, and except for any indemnity claim under Section 19, no claim or action arising out of or relating to this Agreement or any Work Order may be brought by a Party more than
three (3) years after the termination of this Agreement, or an applicable Work Order, whichever is longer. 

  

	33.11	 Law. All matters affecting the interpretation, validity and performance of this Agreement shall be
governed by the laws of Delaware, without regard or giving effect to its principles of conflicts of law and, if applicable, with the express exclusion of the United Nations Convention on the International Sale of Goods. 

 

	33.12	 Jurisdiction. The Parties irrevocably agree that any dispute or claim arising out of or in connection
with this Agreement or its subject matter or formation (including non-contractual disputes or claims) shall be governed by the exclusive jurisdiction of the courts of State of Delaware. 

Signed by the Parties or their duly authorized officers on the dates set forth below, to be effective on the date set forth on the first page
of this Agreement. 

  

			
	Page 26 of 60

									
			
	Galectin Therapeutics Inc.	 		 	Covance Inc.
					
	Signature  	 	/s/ Harold Shlevin	 		 	Signature  	 	/s/ Pam Saker
					
	Name:	 	Harold Shlevin	 		 	Name:	 	Pam Saker
					
	Title:	 	CEO	 		 	Title:	 	Director, Contract Management
					
	Date:	 	March 12, 2020	 		 	Date:	 	March 12, 2020

  

			
	Page 27 of 60

 EXHIBIT A-1 – ADDITIONAL TERMS &
CONDITIONS FOR THE PROVISION OF EARLY DEVELOPMENT SERVICES 
 WHEREAS 
  

	(A)	 GALECTIN THERAPEUTICS INC. (the Sponsor) and COVANCE INC. (the Company) are parties
to a Master Services Agreement effective as of March 12, 2020 (the MSA). 

  

	(B)	 COVANCE LABORATORIES INC. with its principal address of 3301 Kinsman Blvd, Madison, Wisconsin 53704,
USA, together with its Named Affiliates (as defined below), (collectively “CL-ED”) shall be considered parties to the MSA for the Services provided under this Exhibit A-1. 

  

	(C)	 This Exhibit A-1 to the MSA is for the provision of early development
services to the Sponsor by CL-ED. 

 NOW THEREFORE the Parties agree as follows: 

 

	1.	 Definitions 

  

	1.1	 Each capitalized term used in this Exhibit A-1, but not defined, has
the meaning specified in the MSA unless a clear contrary interpretation otherwise applies. 

  

	1.2	 For the purposes of this Exhibit A-1, the following definitions shall
apply: 

 “Inspection Cycle” means the time period between inspections by Regulatory Authorities (if
applicable) which shall be at least annually but will vary between Covance sites and according to applicable Regulatory Requirements. 

“Named Affiliates” mean Covance Bioanalytical Services LLC, with its address of 8211 SciCor Drive, Suite B,
Indianapolis, Indiana, 46214, USA; Covance Laboratories Limited with its registered office at Otley Road, Harrogate, North Yorkshire, HG3 1PY UK, and Covance Preclinical Services GmbH, with its registered office at Kesselfeld 29,
DE48163, Muenster, Germany. 
  

	2.	 Protocol/Scientific Plan 

 

	2.1	 In the absence of a Protocol/Scientific Plan agreed to by the Parties, the Sponsor shall notify CL-ED of the intended regulatory use (if any) of the Study and the applicable Regulatory Requirements to be followed by CL-ED. Notwithstanding any assistance provided by CL-ED in the development of the Protocol/Scientific Plan, CL-ED does not warrant that such Protocol/Scientific Plan sill satisfy the requirements of any Regulatory Authority
at the time of submission. 

  

	2.2	 Where applicable to the Services, the Sponsor and CL-ED shall agree to
a quality agreement detailing the technical and regulatory matters associated with the provision of a Study (Quality Agreement). If there is any inconsistency between the MSA, this Exhibit A-1 and the Quality
Agreement, the Quality Agreement shall prevail for quality and relevant regulatory matters. 

  

	3.	 Form of Contract 

Upon receipt of the Sponsor’s request for Services, Covance shall provide a written quotation pursuant to and referencing this Agreement.
Upon signature by both Parties, a binding contract shall be formed and the document shall become the Work Order for the purposes of this Agreement, and for the purposes of Services provided by CL-ED, Exhibit B
of this Agreement shall not apply. 

  

			
	Page 28 of 60

	4.	 Study Performance, Materials and Resources 

The Sponsor shall provide CL-ED with any relevant occupational safety information known by the Sponsor,
including a safety data sheet (SDS) and, if applicable, a certificate of analysis for the Test Materials. The SDS must conform to globally accepted standards for the applicable Test Materials of the Global Harmonization Standard. 

 

	5.	 Deliverables 

  

	5.1	 All reports shall be prepared in a CL-ED standard format unless
otherwise agreed upon by the Parties. 

  

	5.2	 In the event that six (6) months from the date of the audited draft report (the Draft Report), CL-ED has received neither requested revisions nor instructions to finalise the Draft Report, CL-ED reserves the right to consider the Draft Report as “final” and
issue it as the complete, approved output of the Study (the Final Report). The Final Report shall be signed by CL-ED and submitted to the Sponsor. Any modification or changes to the Final Report shall be
performed at additional cost to the Sponsor. Where required by law or regulation, the Sponsor shall provide a copy of each Draft Report to CL-ED submitted to a regulatory authority within thirty (30) days
of the submission. 

  

	5.3	 The nature of the Services is experimental, and any timelines or quantities shown in the Work Order or
Protocol/Scientific Plan are estimates only. 

  

	6.	 Raw Data and Sample Retention 

 

	6.1	 All experimental data arising from the specific performance of the Services including tissues, blocks, slides,
records, original laboratory accounts of the work performed and authorised documents, but excluding Samples and Test Materials (Raw Data) shall, unless otherwise agreed in the Work Order or Protocol/Scientific Plan be retained by CL-ED for one (1) Inspection Cycle from the date of the Final Report. 

  

	6.2	 In the event that Raw Data is returned to the Sponsor within the Inspection Cycle, the Sponsor agrees that
should the Raw Data be required by a Regulatory Authority conducting an inspection of CL-ED facilities, the Raw Data shall be immediately returned to CL-ED at the
Sponsor’s cost. 

  

	6.3	 Subject to Section 24 of the MSA, all Samples associated with the Services shall be retained, returned or
destroyed in accordance with the Sponsor’s instructions. Where no instructions are received, after ninety (90) days following submission of the first Draft Report the Samples shall be retained by Covance and invoiced to the Sponsor. In the
event that invoices are unpaid and no instructions are received, Covance reserves the right to dispose of the Samples 

  

	6.4	 If the Sponsor instructs CL-ED to retain any Samples or Raw Data beyond
the agreed retention period, CL-ED shall levy a charge on the Sponsor based on the amount and type of materials to be retained. Any Raw Data or samples not required to be retained shall, at the Sponsor’s
cost and expense, either be returned to the Sponsor or destroyed. The Sponsor shall be responsible for any regulatory implications of the fate of the Samples or Raw Data. 

  

			
	Page 29 of 60

	6.5	 CL-ED reserves the right to levy a charge for the handling, tracking,
and storage of any Samples received which are ultimately not required by the Sponsor to be analysed as part of the Services. 

  

	7.	 Fees and Invoices 

 

	7.1	 Any amount shown in the Work Order in respect of a Final Report shall become due and payable if CL-ED has not received any comments from the Sponsor forty-five (45) days after delivery of the Draft Report. 

  

	7.2	 For a Study with a stated duration of more than twelve (12) months,
CL-ED reserves the right to adjust prices annually based on the CPI rates published by the Organisation for Economic Co-operation (OECD) upon thirty (30) days prior
written notice to the Sponsor. CL-ED reserves the right to adjust prices for Services if the initiation of the work is delayed by more than six (6) months beyond the original estimated start date as at
the date of the Work Order. 

  

	8.	 Additional Fees for Delay or Termination for Convenience 

 

	8.1	 In the event that the Study is Delayed for any reason as set out in Section 22.1 of the MSA, the fees
listed in the table below shall be levied to the Sponsor in addition to the amounts due under [*]. 

  

									
	 Notice Period
	  	Study Type	 	 	Charge Incurred	 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	  	 	[	*] 	 	 	[	*] 
	  	 	[	*] 	 	 	[	*] 
	  	 	[	*] 	 	 	[	*] 

  

	*	 Values shown are in USD. Where the fees are in any other currency, the appropriate delay fee shall be applied
based on the average New York or London spot rate for the year. 

  

	8.2	 The Sponsor may terminate a Work Order by giving written notice of such termination to CL-ED in accordance with Section 21.2 of the MSA. In the event the Sponsor terminates a Work Order prior to completion of the Study, the fees listed in the table below shall be levied to the Sponsor in addition
to the amounts due under Section 22.2 of the MSA: 

  

									
	 Notice Period
	  	Charges Incurred	 	 	Administrative Fee	 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 

  

	8.3	 Following a Delay of a Study, if the Sponsor agrees to a revised start date at the convenience of CL-ED, the number of weeks used to calculate the additional fees payable by the Sponsor pursuant to this Paragraph 7 shall be reduced by one (1) week for every two (2) weeks of flexibility that the Sponsor
is willing to move the revised start date. 

  

			
	Page 30 of 60

	9.	 Payment Terms 

The following payment schedule shall be followed for all Work Orders between the Sponsor [*]. 

 

					
	 	  	 Study Type
	  	 Payment Schedule

	 [*]
	  	[*]	  	[*]
		  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
		  	[*]	  	[*]
		  	[*]	  	[*]
		  	[*]	  	[*]

  

			
	Page 31 of 60

	10.	 Notices 

All notices to CL-ED shall be sent to: Covance Laboratories Ltd., Otley Road, Harrogate, North
Yorkshire, HG3 1PY, UK; Attention: Contracts Lead, Early Development. 
 SIGNED by an authorised signatory for and on behalf of: 

 

									
	Galectin Therapeutics Inc.	 		 	Covance Laboratories Inc.
					
	By:	 	 	 		 	By:	 	 
					
	Date:	 	 	 		 	Date:	 	 
				
	    	 		 		 	Covance Inc.
					
		 		 		 	By:	 	 
					
		 		 		 	Date:	 	 

  

			
	Page 32 of 60

 EXHIBIT A-2 – ADDITIONAL TERMS AND CONDITIONS FOR
THE PROVISION OF CLINICAL RESEARCH SERVICES IN CLINICAL TRIAL SUBJECTS 
 WHEREAS 

 

	(A)	 GALECTIN THERAPEUTICS INC. (the Sponsor) and Covance Inc. (the Company or Covance
Clinical) are parties to a Master Services Agreement effective as of March 12, 2020 (the MSA). 

  

	(B)	 This Exhibit A-2 to the MSA is for the provision of clinical research
services in patients to the Sponsor by Covance Clinical. 

 NOW THEREFORE the Parties agree as follows: 

 

	1.	 Definitions 

  

	1.1.	 Each capitalized term used in this Exhibit A-2, but not defined, has
the meaning specified in the MSA unless a clear contrary interpretation otherwise applies. 

  

	2.	 Transfer of Obligations 

 

	2.1.	 Covance Clinical acknowledges and agrees that the responsibility for Services performed as set forth under the
applicable Work Order are being transferred to Covance Clinical in accordance with 21 CFR §312.52, EU Clinical Trial Directive (2001/20/EC), International Conference on Harmonization of GCP E6 (R2) (ICH GCP) or any other applicable regulations.
The Sponsor shall at all times be considered the “Sponsor” of the Study pursuant to the terms of the Federal Food, Drug, and Cosmetic Act (as amended), the regulations of the US FDA (as promulgated in 21 CFR), and the regulations of the US
FDA (as promulgated in 21 CFR) or any other applicable national regulations and ICH GCP. The obligations transferred should be included in Form FDA 1571, Section #14, the EudraCT form or an equivalent in the country in which the Services are being
performed (Transfer of Obligations Form). 

  

	2.2.	 The Parties acknowledge and agree that although Covance Clinical may recommend investigative sites be closed
(for example due to site non-performance), the Sponsor shall retain responsibility for formally approving the closing of such investigative sites. 

 

	2.3.	 For any Change Order that affects the scope of the regulatory obligations that have been transferred to Covance
Clinical, the Sponsor and Covance Clinical shall execute a corresponding amendment to any Transfer of Obligations Form. The Sponsor shall file such amendment where appropriate or as required by any applicable Regulatory Requirements.

  

	3.	 Insurance 

  

	3.1.	 The Sponsor hereby represents and warrants that it maintains adequate clinical trial and product liability
insurance coverage consistent with industry standards through a reputable insurance carrier and in compliance with all applicable Regulatory Requirements with minimum coverage of ten million US dollars (US $10,000,000) per occurrence. The Sponsor
further represents and warrants that such insurance policies shall not contains any additional exclusions clauses not normally found in insurance of such type that might limit and would not extend to the clinical trial for which the Services are
being provided. Covance Clinical hereby represents and warrants that it maintains adequate general liability and errors and omissions / professional liability insurance coverage consistent with industry standards through a reputable insurance
carrier and in compliance with all applicable Regulatory Requirements with minimum coverage of ten million US dollars (US $10,000,000) per occurrence. 

  

			
	Page 33 of 60

	3.2.	 Covance Clinical shall be listed as an additional insured on the Sponsor’s clinical trial policy. The
insurance of Sponsor shall insure Sponsor and Covance Clinical against third party claims asserted by all subjects screened or treated as part of the relevant clinical trial for personal injury suffered as a result of the participation in the Study
and/or the Study screening process. Upon request Sponsor shall be listed as an additional insured on Covance’s general liability insurance coverage. 

  

	3.3.	 The Sponsor and Covance Clinical shall each provide the other with a copy of its certificate of insurance to
confirm that it has such insurance coverage. The insurance of each of Sponsor and Covance Clinical shall be with a company having a minimum of an A-rating by Best’s rating service. The Sponsor shall
maintain such insurance through the entire duration of Study and for three (3) years thereafter and shall immediately notify Covance Clinical in writing of any changes in coverage that impact the coverage requirements set forth above. In the
event coverage is not maintained, a minimum three (3) year extended reporting period shall be purchased by the Sponsor. 

  

	3.4.	 In the event that either the Sponsor or Clinical Covance is unable to provide an appropriate:
(i) certificate of insurance; or (ii) level of insurance cover as specified in this Paragraph 3, then the other party shall be entitled to terminate the relevant Work Order in which case the relevant Services thereunder will cease.

  

	4.	 Delays or Cancellation 

 

	4.1.	 In the event that a Study is Delayed or placed on-hold for more than
thirty (30) calendar days the Sponsor shall have the right to retain at their expense all core team members as defined in the applicable Work Order on a full time equivalent basis for the duration of the delay or
on-hold period. If the Sponsor does not wish to retain any core team members for the duration of the on-hold or Delay period, Covance Clinical shall have the right to
reallocate any and all such staff after a thirty (30) calendar day period. If the Delay or on-hold period continues for ninety (90) days either Party may, by provision of written notice, terminate
the applicable Work Order. 

  

	4.2.	 If the scheduled start-up of any Study under a Work Order to this
Exhibit A-[ 2] is Delayed or cancelled by the Sponsor, pursuant to Section 22 of the MSA, Covance Clinical shall be entitled to payment in full on a time and materials basis for all work properly
performed by Covance Clinical for the Services (inclusive of wind-down costs) up through the effective day or Delay or termination regardless of: (i) the achievement of any milestones used as payment triggers for Fixed Price Work Orders or
(ii) the achievement of any units or partial units as outlined in the Budget for Fixed Unit Price Work Orders. 

  

	5.	 Data Management Services 

 

	5.1.	 According to Covance Clinical’s licensing agreements, Covance Clinical is prohibited from sharing
dictionary terminology or data with any non-subscribing client. In offering Covance Clinical’s coding services for a particular Study, the Sponsor undertakes that it has or shall obtain a current
subscription for using such coding with the applicable licensor (including, Northrop Grumman/MSSO for MedDRA and Uppsala Monitoring Center for WHODRUG). Covance shall assist Sponsor in obtaining such subscription(s) 

 

	5.2.	 Covance Clinical is required to verify the Sponsor’s subscription to such dictionary and data services
before the start of a particular Study. If it is determined that the Sponsor does not have an appropriate subscription, Covance Clinical shall have the right to: (a) inform the applicable licensor; (b) cease provision of any of the
terminology or data; and (c) be reimbursed all costs, expenses and damages associated with Sponsor’s failure to be properly licensed to use such dictionary and data services. 

  

			
	Page 34 of 60

	6.	 Notices 

All notices to Covance Clinical shall be sent to Covance Inc., 210 Carnegie Center, Princeton, NJ 08540-6233, USA, Attention: Global Director
Contract Management. 
 SIGNED by an authorised signatory for and on behalf of: 
  

									
	Galectin Therapeutics Inc.	 		 	Covance Inc.
					
	By:	 	   
	 	            	 	By:	 	   

					
	Date:	 	 	 		 	Date:	 	 

  

			
	Page 35 of 60

 EXHIBIT A-3 – ADDITIONAL TERMS AND CONDITIONS FOR
THE PROVISION OF CENTRAL LABORATORY TESTING SERVICES 
 WHEREAS 
  

	(A)	 GALECTIN THERAPEUTICS INC. (the Sponsor) and Covance Inc. (the Company) are parties
to a Master Services Agreement effective as of March 12, 2020 (the MSA). 

  

	(B)	 COVANCE CENTRAL LABORATORY SERVICES LP an Indiana limited partnership, with its principal place of
business at 8211 SciCor Drive, Indianapolis, Indiana 46214, USA; and COVANCE CENTRAL LABORATORY SERVICES SÀRL, with its principal place of business at Rue Moise-Marchines 7, 1217 Meyrin, Geneva Switzerland (collectively CCLS)
shall be considered to be a parties to the MSA for the Services provided under this Exhibit A-3. 

  

	(C)	 This Exhibit A-3 to the MSA is for the provision of central laboratory
testing services to the Sponsor by CCLS. 

 NOW THEREFORE the Parties agree as follows: 

 

	1.	 Definitions 

  

	1.1.	 Each capitalized term used in this Exhibit A-3, but not defined, has
the meaning specified in the MSA unless a clear contrary interpretation otherwise applies. 

  

	2.	 Advance Payments 

 

	2.1.	 Upon execution of a Work Order, CCLS shall assess a fee equal to [*] of the value of the Budget (Deposit).

  

	2.2.	 Each month, CCLS shall invoice the Sponsor for all fees due and pass through costs incurred while providing
Services during the previous month. The Deposit shall be retained by Covance until the Study reaches final account reconciliation. CCLS will issue repayment of the balance of the Deposit by first applying it to outstanding unpaid invoices.

  

	2.3.	 If the Study is terminated before the Deposit is exhausted, and assuming all prior invoices have been paid by
the Sponsor, CCLS shall apply the Deposit funds to the final invoice, then refund any remaining Deposit funds to the Sponsor within sixty (60) days. 

  

	3.	 Payment Dispute 

In the event Sponsor disputes any charge in an invoice Sponsor may elect to withhold payment for the portion of the invoice that is in dispute,
but shall pay any undisputed amounts in accordance with the payment terms provided in Section 8.3. The Parties hereby agree to use good faith efforts to reconcile the disputed amount as soon as practically possible. If the resolution of such
dispute results in a credit to Sponsor, such credit will be reflected on the next monthly invoice of the applicable Work Order. 
  

	4.	 Additional Services 

 

	4.1.	 If the Sponsor requests additional Services that require modifications to an existing Protocol/Scientific Plan,
CCLS will provide the Sponsor with the revised Protocol/Scientific Plan for review and approval. 

  

	4.2.	 Notwithstanding Section 10 of the MSA, upon CCLS’ receipt of the Sponsor’s written approval of
the revised Protocol/Scientific Plan (as evidenced by Sponsor’s signature on the revised Protocol/Scientific Plan), CCLS shall provide such services to the Sponsor and the Sponsor shall pay for costs associated with such services at its current
standard rates. 

  

			
	Page 36 of 60

	4.3.	 During performance of Services, CCLS may be required to provide certain items including but not limited to
ancillary supplies, logistics and minor modifications to database design (the Items). [*] 

  

	5.	 Billing and Invoicing 

 

	5.1.	 For budgeting purposes, CCLS creates a Budget using local unit pricing which is then converted to the billing
currency, as agreed between the Parties using the Reuters exchange rate at the time the Budget is first created. Unless specified otherwise, this exchange rate remains unchanged during the course of the Study to simplify Budget comparisons and
enable the Sponsor to track changes to the Study unrelated to changes in currency exchange rates. 

  

	5.2.	 For invoicing purposes, Services are billed based on the contracted local unit prices. Each month, at the time
of invoice creation, the local unit prices are converted to the billing currency using the Reuters exchange rate for the month in which the Services were performed. 

 

	5.3.	 [*] 

  

	6.	 Auditing 

Where an audit of CCLS concerns or relates to referral laboratory testing or shipping methods of CCLS, the Sponsor or its representative (which
shall not be a competitor of Covance) may only confirm whether or not CCLS is properly billing such costs. The Sponsor expressly agrees that Sponsor’s representatives may not directly or indirectly provide any details of the charges to the
Sponsor, such as the actual amount of the referral laboratory testing or shipping costs incurred by CCLS. 
  

	7.	 Transportation Charges 

Shipping costs are included in the Budget of the applicable Work Order as estimated pass-through costs. For the avoidance of doubt, shipping
costs charged to the Sponsor within an applicable Work Order shall be inclusive of a logistical support fee with respect to the management and tracking of specimens. 
  

	8.	 Provision of Kits 

 

	8.1.	 In accordance with the Work Order, CCLS shall provide each Investigator site with Study and visit specific
specimen collection supplies needed to collect and ship specimens back to CCLS for analysis (Specimen Kit). Each Specimen Kit may include test tubes, pipettes, collection needles and other required materials together with instructions for collection
and shipment. Specimen Kits shall also have a test requisition form or other instructions to allow for the electronic capture of such data designated for the particular Study. Each Specimen Kit shall be barcoded to ensure tracking and testing audit
trails upon its return to CCLS. 

  

	8.2.	 In the event that a Specimen Kit is lost, expired or otherwise rendered unusable for reasons outside the
CCLS’ reasonable control or should a Specimen Kit expire at an Investigator site, CCLS shall replace such Specimen Kits at a cost equal to the amount listed in the Budget of the applicable Work Order for each Specimen Kit that is replaced.

  

			
	Page 37 of 60

	9.	 Storage of Samples 

CCLS shall not destroy any Samples without giving prior written notice to Sponsor and giving Sponsor a reasonable opportunity to provide
directions for the Samples to be sent to a different location for storage. If Sponsor does not respond to CCLS’s request for Sample disposition within thirty (30) days, CCLS may return such Samples to Sponsor at Sponsor’s cost.
CCLS’s liability for any breach or default for the storage of Samples shall not exceed the fees it has been paid for storage of such Samples for the previous twelve (12) months. 

 

	10.	 Samples During Force Majeure 

 

	10.1.	 In the event of Force Majeure Event, CCLS shall take all reasonable commercial steps to re-route Samples to another CCLS facility or to another qualified laboratory for testing.  

  

	10.2.	 If the Samples are routed to a non-CCLS laboratory for testing, the
Sponsor agrees to pay all fees and charges related to those samples and testing. 

  

	11.	 Notices 

All notices to CCLS shall be sent to Covance Central Laboratory Services LP, 8211 SciCor Drive, Indianapolis, Indiana 46214, USA, Attention: VP
Finance. 

  

			
	Page 38 of 60

 SIGNED by an authorised signatory for and on behalf of: 

 

									
	Galectin Therapeutics Inc.	 		 	Covance Central Laboratory Services LP
					
	By:	 	   
	 	            	 	By:	 	   

					
	Date:	 	 	 		 	Date:	 	 
		
		 	Covance Central Laboratory Services Sàrl
					
	  
	 	  
	 	            	 	By:	 	   

					
		 		 		 	Date:	 	 
		
		 	Covance Inc.
					
	  
	 	  
	 	            	 	By:	 	   

					
		 		 		 	Date:	 	 

  

			
	Page 39 of 60

 EXHIBIT A-4 - ADDITIONAL TERMS & CONDITIONS
FOR THE PROVISION OF PHASE I HEALTHY VOLUNTEER CLINICAL RESEARCH SERVICES 
 WHEREAS 

 

	(A)	 GALECTIN THERAPEUTICS INC. (the Sponsor) and Covance Inc. (the Company) are parties
to a Master Services Agreement effective as of March 12, 2020 (the MSA). 

  

	(B)	 COVANCE CLINICAL RESEARCH UNIT INC. with its principal address of 3402 Kinsman Blvd, Madison, Wisconsin
53704, USA; and COVANCE CLINICAL RESEARCH UNIT LIMITED with its registered office at Springfield House, Hyde Street, Leeds, LS2 9LH, UK (collectively CRU) shall be considered to be parties to the MSA for the Services provided under
this Exhibit A-4. 

  

	(C)	 This Exhibit A-4 to the MSA is for the provision of Phase 1 healthy
volunteer clinical research services to the Sponsor by the CRU. 

 NOW THEREFORE the Parties agree as follows: 

 

	1.	 Definitions 

  

	1.1.	 Each capitalized term used in this Exhibit A-4, but not defined, has
the meaning specified in the MSA unless a clear contrary interpretation otherwise applies. 

  

	1.2.	 For the purposes of this Exhibit A-4, the following definitions shall
apply: 

 “Completion” means the final visit by the last subject for the relevant Study. 

“Forgone Revenue” means the revenue that would have been earned by CRU under a Work Order if the Sponsor had not cancelled or
Delayed the Study (or part thereof) (such as lost bed space that had been reserved for Sponsor); and 
 “Scheduled Start
Date” means the first subject first visit for a particular Study under a Work Order. 
  

	2.	 Transfer of Obligations 

 

	2.1.	 The CRU acknowledges and agrees that the responsibility for Services performed as set forth under the
applicable Work Order are being transferred to the CRU in accordance with 21 CFR §312.52, EU Clinical Trial Directive (2001/20/EC), International Conference on Harmonization of GCP E6 (R2) (ICH GCP) or any other applicable regulations.
The Sponsor shall at all times be considered the “Sponsor” of the Study pursuant to the terms of the Federal Food, Drug, and Cosmetic Act (as amended) and the regulations of the US FDA (as promulgated in 21 CFR) or any other applicable
national regulations and ICH GCP. The obligations transferred should be included in Form FDA 1571, Section #14, the EudraCT form or an equivalent in the country in which the Services are being performed (Transfer of Obligations Form).

  

	2.2.	 For any Change Order that affects the scope of the regulatory obligations that have been transferred to the
CRU, the Sponsor and CRU, shall execute a corresponding amendment to any Transfer of Obligations Form. The Sponsor shall file such amendment where appropriate or as required by applicable Regulatory Requirements. 

 

	3.	 Safety Data and Clinical Holds 

The Sponsor shall promptly inform the CRU in writing in accordance with all applicable Regulatory Requirements if: (i) the Sponsor is
aware of any safety data from any source which is applicable to the Study and which may indicate a negative impact on subject safety or well-being; or (ii) if there is a clinical hold on the Study by the applicable Regulatory Authority. 

  

			
	Page 40 of 60

	4.	 Volunteer Compensation for UK Phase I Trials 

Where applicable, the Sponsor agrees to abide by the current Association of the British Pharmaceutical Industry “Guidelines for Phase 1
Clinical Trials” (the Guidelines) and agrees that it understands the section entitled “Risk Management”. The Guidelines may be found at the following link: http://www.abpi.org.uk/our-work/library/guidelines/Pages/phase-1-trials-2012.aspx. 
  

	5.	 Informed Consent Forms 

The Sponsor hereby directs and authorizes the CRU to act as the Sponsor’s agent with actual authority to enter into and execute for and on
behalf of the Sponsor and in the Sponsor’s name a subject informed consent form for each volunteer study performed under the Agreement and a Work Order in accordance with all applicable Regulatory Requirements. The current informed consent form
template is available upon request. 
  

	6.	 CRU Data Management Services 

 

	6.1.	 According to the CRU’s licensing agreements, the CRU is prohibited from sharing dictionary terminology or
data with any non-subscribing client. In offering the CRU’s coding services for a particular Study, the Sponsor undertakes that it has or shall obtain a current subscription for using such coding with the
applicable licensor (including, Northrop Grumman/MSSO for MedDRA and Uppsala Monitoring Center for WHODRUG). 

  

	6.2.	 The CRU is required to verify the Sponsor’s subscription to such dictionary and data services before the
start of a particular Study. If it is determined that the Sponsor does not have an appropriate subscription, the CRU shall have the right to: (a) inform the applicable licensor; (b) cease provision of any of the terminology or data; and
(c) be reimbursed all costs, expenses and damages associated with Sponsor’s failure to be properly licensed to use such dictionary and data services. 

 

	7.	 Record Storage and Retention 

 

	7.1.	 All reports shall be prepared in the CRU’s standard format unless otherwise specified in the Work Order.

  

	7.2.	 All primary investigator-related data generated by the CRU, or copies thereof (for example, laboratory records,
CRFs, data sheets, correspondence, photographs and computer records etc.) that are a result of the original observations and activities of the Study and are necessary for the reconstruction and evaluation of the Study (Investigator Records)
shall, unless specifically stated otherwise in the Work Order or Protocol/Scientific Plan, be collated by the CRU after issuing the final report. The Investigator Records shall be retained as required under current regulatory requirements after
Completion of the Study. 

  

	7.3.	 Frozen Samples shall be shipped to the appropriate analytical laboratory according to the Sponsor’s
instructions or other requirements in the Work Order or Protocol/Scientific Plan. All other frozen Samples (e.g. secondary/backup or unanalysed samples) shall be retained by the CRU for a period of six (6) months after Completion unless
otherwise specified in the Work Order or Protocol/Scientific Plan. Refrigerated Samples shall be retained for one (1) week after their analysis and then destroyed unless otherwise agreed upon by the Parties (each a Retention Period).

  

			
	Page 41 of 60

	7.4.	 The Budget shall include the costs for archiving frozen Samples for the relevant Retention Period. At the end
of the relevant Retention Period, the CRU shall contact the Sponsor to determine if a longer Retention Period for each of the Samples is required. If a longer retention period is not required, CRU shall ship the samples to the archive facility of
the Sponsor’s choice at Sponsor’s expense 

  

	7.5.	 Where the Sponsor wishes the CRU to retain the Samples beyond the relevant Retention Period and/or Investigator
Records beyond the current Regulatory Requirements, the CRU shall levy a periodic charge on the Sponsor based on the amount and type of materials retained. All records, raw data, Samples and materials not required for retention shall, at the
Sponsor’s expense, either be returned to the Sponsor or destroyed. The Sponsor shall be responsible for any regulatory implications of either option. 

  

	8.	 Insurance 

  

	8.1.	 The Sponsor hereby represents and warrants that it maintains adequate separate clinical trial and product
liability insurance coverage consistent with industry standards through a reputable insurance carrier and in compliance with all applicable Regulatory Requirements. The sum insured shall be in compliance with all applicable Regulatory Requirements,
but shall not be less than five million pounds sterling (£5,000,000) per occurrence for trials in the UK or five million US dollars ($5,000,000) per occurrence for trials in the US, except where the Study is a first-in-human study, where the minimum coverage of such insurance shall ten million US Dollars (US $10,000,000) per occurrence. The Sponsor further represents and warrants that such insurance policies shall
not contain any additional exclusion clauses not normally found in insurance of this type that might limit such cover for the Study. CRU hereby represents and warrants that it maintains adequate general liability and errors and omissions /
professional liability insurance coverage consistent with industry standards through a reputable insurance carrier and in compliance with all applicable Regulatory Requirements with minimum coverage of ten million US dollars (US $10,000,000) per
occurrence. 

  

	8.2.	 The insurance of Sponsor shall identify the CRU as an additional insured and shall cover all subjects screened
or treated as part of the Study for personal injury suffered as a result of the participation in the Study and/or the Study screening process. Upon request Sponsor shall be listed as an additional insured on CRU’s general liability insurance
coverage. 

  

	8.3.	 The Sponsor and CRU shall each provide the other with a copy of its certificate of insurance or such other
documented evidence to confirm that it has such insurance coverage. For the avoidance of doubt, a statement of self-insurance is not acceptable. The insurance of each of Sponsor and Covance shall be with a company having a minimum of an A-rating by Best’s rating. The Sponsor and CRU shall maintain such insurance through the entire duration of Study and for the duration according to applicable Regulatory Requirements, which shall be at least
three (3) years thereafter. The Sponsor shall immediately notify the CRU in writing of any changes in coverage that affects the requirements above. In the event coverage is not maintained, a minimum three (3) year extended reporting period
must be purchased by the Sponsor 

  

	8.4.	 In the event that the Sponsor or CRU is unable to provide an appropriate: (i) certificate of insurance; or
(ii) level of insurance cover as specified in this Paragraph 8, then the CRU shall be entitled to cease the relevant Services whereupon the relevant Work Order may be terminated. 

 

	9.	 Additional Fees for Delay or Termination for Convenience 

 

	9.1.	 Except to the extent that any Services under a Work Order are Delayed or cancelled as a result of the
CRU’s breach of the Work Order, if the Scheduled Start Date to this Exhibit A-4 is Delayed or cancelled by the Sponsor within the following time periods, the Sponsor shall pay the CRU the following fees
in addition to the amounts due under Section 22 of the MSA: 

  

			
	Page 42 of 60

	 	9.1.1.	 if the Services are cancelled or Delayed: (i) [*] before the Scheduled Start Date; or (ii) at any time
where more than [*] of the Budget payable under a particular Work Order have been incurred and invoiced to the Sponsor[*]; 

  

	 	9.1.2.	 if the Services are cancelled [*], the Sponsor shall pay the CRU [*]; 

 

	 	9.1.3.	 if the Services: (i) are cancelled [*] before the Scheduled Start Date; or (ii) are cancelled after
[*], the Sponsor shall pay the CRU a fee of [*]; 

  

	 	9.1.4.	 if the Study or part of the Study is Delayed by [*], the Sponsor shall pay the CRU [*]. If the CRU is unable to
reschedule the Study or part of the Study on the date requested by the Sponsor and the Sponsor elects to cancel the Study (or part thereof), [*]. 

  

	9.2.	 Pursuant to Paragraphs 9.1.2 and 9.1.3, the additional fee shall be calculated on the standard rates of the CRU
personnel assigned to the affected Work Order, provided that such personnel’s time is not already being billed to the Sponsor for close out activities. The CRU shall act in good faith and use its reasonable commercial endeavours to promptly re-assign such personnel. 

  

	10.	 Third Party Investigator Sites 

 

	10.1.	 If the Sponsor requests that the CRU contracts with an Investigator for conduct of a Study, the Sponsor shall
provide the authority for the CRU to contract with the Investigator on behalf of the Sponsor. Any indemnification rights granted to the Investigator shall be provided exclusively by the Sponsor and in the event that the Investigator invokes such
rights, the Investigator shall deal directly with the Sponsor. 

  

	10.2.	 The Parties agree that Investigators shall be deemed to be independent contractors exercising independent
judgment and shall not be considered either Subcontractors or Vendors of the CRU. The CRU’s responsibility in connection with the contract with the Investigator shall be for the CRU to make payments that are payable to Investigator in
connection with its services in accordance with the respective budget for the Investigator, (such budget shall be subject to review and approval by the Sponsor). The CRU shall cooperate with the Sponsor in accordance with the Sponsor’s
instructions in enforcing the contract with the Investigator sites. 

  

	11.	 Notices 

  

	11.1.	 For Phase 1 CRU services in the US, all notices shall be sent to Covance Clinical Research Unit Inc. 3402
Kinsman Boulevard, Madison, Wisconsin 53704, USA; Attention: Manager Contract Management. 

  

	11.2.	 For Phase 1 CRU services in the UK, all notices shall be sent to Covance Clinical Research Unit Ltd.,
Springfield House, Hyde Street, Leeds West Yorkshire, LS2 9LH, UK; Attention: Managing Director. 

 SIGNED by an authorised signatory for
and on behalf of: 
  

									
	Galectin Therapeutics Inc.	 		 	Covance Clinical Research Unit Inc.
					
	By:	 	 	 		 	By:	 	 
					
	Date:	 	 	 		 	Date:	 	 

  

			
	Page 43 of 60

 
			
	Covance Clinical Research Unit Limited
		
	By:	 	 
		
	Date:	 	 

  

			
	Covance Inc.
		
	By:	 	 
		
	Date:	 	 

  

			
	Page 44 of 60

 EXHIBIT B1 - PRO-FORMA WORK ORDER: LEGAL REPRESENTATIVE
SERVICES 
 This WORK ORDER is made the date the last party signs below between: 

 

	(1)	 Galectin Therapeutics Inc. whose registered office is at Suite 240, 4960 Peachtree Industrial Boulevard,
Norcross, Georgia 30071 (the Sponsor); and 

  

	(2)	 COVANCE [    ] whose registered office is at [insert address]
(Covance), 

 (each a Party and collectively the Parties). 

RECITALS 
  

	(A)	 WHEREAS Sponsor and Covance are parties to a Master Services Agreement effective as of March 12, 2020 (the
MSA). 

  

	(B)	 WHEREAS subject to the terms and conditions of the MSA [and the additional terms and conditions set forth in
[insert any relevant Exhibits]], the Sponsor and Covance hereby agree to execute a Work Order relating to the Services for Sponsor’s Protocol/Scientific Plan [insert reference]. 

NOW THEREFORE the Parties agree as follows: 
  

	1.	 Definitions and Interpretation 

 

	1.1.	 Each word and term used in this Work Order, but not defined, has the meaning specified in the MSA unless a
clear contrary interpretation otherwise applies. 

  

	1.2.	 In this Work Order, unless the context otherwise requires, the following words and expressions shall have the
following meanings: 

 “Legal Representative” shall mean Covance’s role in providing the Legal
Representation Services to the Sponsor. 
 “Legal Representation Services” shall mean Covance’s agreement to act as the
agent of the Sponsor as legal representative in [ insert relevant country/region] and to provide the Services described at Annex 1 to this Work Order under the heading “Legal Representation Services”. 

 

	1.3.	 In the event of conflict between the terms and conditions of this Work Order and those of the MSA, the terms of
the MSA shall prevail except to the extent that this Work Order expressly and specifically states an intent to supersede the MSA on a specific matter. 

  

	2.	 Term and Termination 

The term of this Work Order [shall commence on ...] [shall be deemed to have commenced on ...] and shall continue until completion of the
Services or earlier termination of the MSA in accordance with the termination provisions set out in the MSA (the Term).  
  

	3.	 Services 

  

	3.1.	 The Parties acknowledge that the Services (as defined in the MSA) include the Legal Representation Services.
For the avoidance of doubt, Legal Representation Services shall not include any services relating to compliance with any Data Protection Laws in [country], which shall remain the responsibility of the Sponsor. 

  

			
	Page 45 of 60

	3.2.	 Covance agrees to perform the following Services for the Sponsor as set forth in the attached description of
Services at Annex 1, which shall also detail the Study/Services Specific Assumptions that apply to the Services. 

  

	4.	 Budget 

  

	4.1.	 The Budget for the Services is set out in the detailed Budget in this Work Order attached at Annex 2.

  

	4.2.	 In consideration for its performance of the Services under this Work Order, the Sponsor shall pay Covance in
accordance with the payment schedule or payment terms set out in this Work Order attached as Annex 3. 

  

	4.3.	 Invoices are due within thirty (30) days of receipt by the Sponsor. 

 

	5.	 Payment and Invoice Details 

 

	5.1.	 All invoices to the Sponsor should be sent to the following address: 

[insert] 
  

	5.2.	 All payments to Covance should be sent to the following address:  

Covance Inc. 
 210 Carnegie Center

 Princeton, New Jersey 08540-6233 

United States 
 Attention:
[insert] 
  

	6.	 Change Control 

In the event that any of the Assumptions used to calculate the Budget or in the provision the Services change, in accordance with Section
[insert – NB: usually section 10] of the MSA, the Parties shall negotiate an amendment to this Work Order if appropriate. No amendment to this Work Order shall be binding unless agreed in writing. 

 

	7.	 Power of Attorney 

The Power of Attorney appended to this Work Order at Annex 4 shall be completed by the Parties and executed appropriately prior to the
commencement of the Legal Representation Services. The Parties acknowledge that the Power of Attorney shall give Covance the authority to act as Legal Representative for the Sponsor when providing the Legal Representation Services. 

 

	8.	 Insurance 

This paragraph shall replace Section 23 of the MSA. The Sponsor hereby represents and warrants that it maintains adequate separate
clinical trial insurance and product liability coverage consistent with industry standards and in compliance with all Regulatory Requirements through a reputable insurance carrier having a minimum of an
A-rating by Best’s rating service or higher which shall have a minimum discovery period of three (3) years inclusive of the period covering clinical trials insurance. For the avoidance of doubt,
if the certificate of liability covers a period of twelve (12) months, the insurance coverage must include an extended reporting period of an 

  

			
	Page 46 of 60

 
additional two (2) years. Sponsor shall be required to maintain such insurance through the life of the study and shall notify Covance in writing of any changes in coverage which impact
requirements set forth above. The sum insured shall not be less than ten million US dollars (US $10,000,000) per occurrence. The Sponsor further represents and warrants that such insurance policies shall not contains any additional exclusions
clauses not normally found in insurance of such type that might limit and would not extend to the study for which the Services are being provided. Covance shall be an additional insured under Sponsor’s policy of insurance. The insurance of
Sponsor shall insure against third party claims asserted by all subjects screened or treated as part of the Study for personal injury suffered as a result of the participation in the Study and/or the Study screening process. 

 

	9.	 Termination 

  

	9.1.	 Should the Sponsor: (a) reduce the level of Services (including the Legal Representation Services) to be
provided by Covance to the extent that it is no longer commercially viable for Covance to perform the Legal Representation Services for the Sponsor; (b) become eligible to assume responsibilities of legal representative itself; (c) unable
to provide the level and form of insurance required as specified above at Section 8; or (d) any regulatory or statutory requirement prevents the provision of Legal Representation Services by Covance, it shall notify Covance promptly in
writing. Covance shall, upon written notice from the Sponsor have the right to: (a) terminate any Legal Representation Services; and/or (b) refuse any additional or revised Legal Representation Services which are not already ongoing under
the relevant Work Order. 

  

	9.2.	 In the event that Covance terminates the Legal Representation Services under this Work Order, it shall cease to
be the Legal Representative of the Sponsor in respect of the Services provided hereunder. 

  

	10.	 Entire Agreement 

This Work Order (including any annexes hereto) and the terms of the MSA represent the entire and integrated agreement between the Sponsor and
Covance and supersede all prior negotiations, representations or agreements, either written or oral, regarding the Services. 
  

	11.	 Choice of Law and Jurisdiction 

Any contractual dispute or claim arising between the Parties to this Work Order arising out of or in connection with the MSA or the Services
defined herein shall be construed, governed, interpreted, and applied in accordance with the provisions of Section 33.11 of the MSA. 
  

									
	Galectin Therapeutics Inc.	 		 	Covance [    ]:
					
	Name:	 	 	 		 	Name:	 	 
					
	Signature:	 	 	 		 	Signature:	 	 
					
	Title:	 	 	 		 	Title:	 	 
					
	Date:	 	 	 		 	Date:	 	 

  

			
	Page 47 of 60

 ANNEX 1 – DESCRIPTION OF SERVICES 

 

	1.	 Legal Representation Services 

 

	1.1.	 The Parties have agreed that Covance shall provide the Legal Representation Services which shall form part of
the Services to be provided under this Work Order. Covance shall perform the Legal Representation Services in compliance with [insert relevant clinical trial law], which shall include the following, in each case, only in relation to the Study:

  

	 	a)	 provision of a contact address, fax number, telephone number and e-mail
address along with any other necessary contact details to Regulatory Authorities for the purpose of communications with such Regulatory Authorities and third parties in connection with Covance’s role as the Sponsor’s Legal Representative;

  

	 	b)	 provision of an individual employee of Covance who shall be familiar with the Study and shall act as a contact
or liaison with Regulatory Authorities and third parties in connection with Covance’s role as the Legal Representative of the Sponsor; 

  

	 	c)	 where reasonably necessary in accordance with Regulatory Requirements, assisting the Sponsor in notifying or
obtaining approval from the relevant Regulatory Authorities in respect of its appointment and in consultation with the Sponsor, preparation of any other documents that are necessary to confirm or formalise such appointment or to inform third
parties; 

  

	 	d)	 preparation and signing of applications, notifications and other documents in connection with the Study
(including, as applicable, letters of authority, applications for clinical trial authorisations and ethical approvals, applications for amendments thereto and notifications of the termination or completion of the Study); 

 

	 	e)	 where Covance expressly takes responsibility for compiling the clinical trial application, supervision,
preparation and submission of such clinical trial application to any relevant Regulatory Authorities within [specify relevant Country or region]; 

  

	 	f)	 performance of all other tasks and activities, including communication, where necessary, with the relevant
Regulatory Authorities and as required in connection with the appointment and fulfilment of the regulatory obligations of Covance as the Sponsor’s Legal Representative; 

 

	 	g)	 seeking and obtaining the Sponsor’s instructions and approval before communicating with Regulatory
Authorities and other third parties or performing any other task or activity in connection with Covance’s role as Legal Representative, provided that where urgent action is required (e.g. an urgent request is received from a Regulatory
Authority) and Covance does not have and is not able to obtain instructions or approval from the Sponsor in the time available, then Covance shall take such action as it reasonably believes to be in the best interests of the Sponsor;

  

	 	h)	 promptly supply to the Sponsor copies of all relevant communications made or received by Covance in connection
with Covance’s role as Legal representative; 

  

	 	i)	 promptly notify the Sponsor of and attend and report on any meetings or hearings involving Covance in
connection with Covance’s role as Legal Representative, provided that, where requested by the Sponsor, Covance shall use all reasonable efforts to ensure that representatives of Sponsor are also permitted to attend such meetings and hearings;
and 

  

	 	j)	 in the event that legal proceedings are instigated in the [Territory specify relevant Country or
region],    accept the service of legal documents, but not including payment of legal, consultancy, medical, specialist or expert fees associated with any claim made against either Covance or the Sponsor.

  

			
	Page 48 of 60

	1.2.	 Subject to Covance acting as the Legal Representative of the Sponsor under the Agreement, the Sponsor
represents and warrants that: 

  

	 	a)	 it shall review all information and material contained or referenced in all clinical trial notifications
(CTNs) and all clinical trial applications or similar required documents (CTAs) for the investigational medicinal product to be tested or used in the performance of the Study as provided to Covance by the Sponsor or that are subject of
the Services provided by Covance hereunder (Test Materials) to ensure that all such information and material is accurate, complete and not false or misleading; 

 

	 	b)	 it will provide sufficient amounts of the Test Materials as required by law or as reasonably requested by
Covance; 

  

	 	c)	 the Test Materials shall be manufactured, packaged and (except to the extent that labelling, coding and
distribution is to be provided as Services under the Agreement pursuant to a Work Order) labelled, coded and distributed in compliance with all applicable laws, rules, regulations and procedures, including Good Manufacturing Practice;

  

	 	d)	 at the close of the Study, the Sponsor shall retain any and all records relating to the Study, including
records received from Covance and shall maintain those records for twenty-five years or such other longer period of time as required by law. In addition, the Sponsor shall make such records available for inspection by any applicable Regulatory
Authority; and 

  

	 	e)	 the Sponsor shall provide to Covance all such information as Covance may reasonably request from time to time
and/or as may be necessary to enable Covance to perform all responsibilities as the Legal Representative for the Sponsor. The Sponsor shall provide all safety information pertinent to the Test Materials to Covance including, all Serious Adverse
Event reports, consistent with applicable requirements as necessary to maintain in a legally compliant manner, all CTNs and CTAs. 

  

	1.3.	 The Sponsor shall indemnify, defend and hold harmless [*] from any Loss resulting from any means, any claim,
demand, assessment, action, suit, proceeding, settlement or investigation arising from or related any liability imposed on the Covance Group as a result of its responsibilities as a Legal Representative, local sponsor or a similar role for the
Sponsor under this Work Order; provided that Sponsor shall not be obliged to indemnify, defend or hold harmless Covance to the extent any Loss arises from (i) any act or omission of Covance, their Affiliates or Subcontractors or Vendors that is
a breach of any provision of the Agreement, Work Order or this Annex; (ii) any negligence, recklessness or wilful misconduct of Covance, their Affiliates or Subcontractors or Vendors; or (iii) any losses arising from Covance, or their
respective Affiliate’s or Subcontractor’s or Vendor’s failure to mitigate any such claim, demand, assessment, action, suit, proceeding, settlement, investigation 

 

	2.	 Services 

[insert any other general Services] 

  

			
	Page 49 of 60

 ANNEX 2 – BUDGET 

The pricing for the Work Order shall be deemed to be a Fixed [Unit] Price Work Order, which means a fixed set of Services and delivered in accordance with the
fixed [fees]/[unit budget] outlined in this Annex. 
 Additional paragraph for Fixed Unit Price: Fixed Unit Prices reflect the average unit price to
perform the task and are not illustrative of the actual effort associated with the unit. If the scope of an individual unit changes or the projected number of units are not achieved, adjustments shall be made to the Fixed Unit Price or the
development of a new unit (as the case may be) in accordance with Section 10 of the MSA to reflect the actual effort associated with the unit.] 

  

			
	Page 50 of 60

 ANNEX 3 – PAYMENT SCHEDULE OR PAYMENT TERMS 

[insert] 

  

			
	Page 51 of 60

 ANNEX 4 – POWER OF ATTORNEY FOR LEGAL REPRESENTATION SERVICES 

THIS POWER OF ATTORNEY is made on [insert date] by, a company with its [principal place of business] [registered office] at [insert address] and
[registered number [insert if applicable]] (the “Principal”). 
  

	1.	 APPOINTMENT AND POWERS 

 

	 	1.1	 The Principal hereby appoints COVANCE INC. with its principal place of business at 210 Carnegie Center,
Princeton, New Jersey, 08540 USA as its attorney in fact (the “Attorney”) and gives authority for the Attorney to act in the Principal’s name or otherwise and on its behalf to the extent necessary to perform the following
activities relating to the conduct of the clinical trial under Protocol Number:[insert] and with study title: [“insert name of Study”] (the “Clinical Trial”) and provided that any powers granted herein shall apply
only to the conduct of the Clinical Trial in [insert relevant country/region]: 

  

	 	(a)	 prepare and sign documents required for the Clinical Trial by the local ethics committees and central ethics
committees; 

  

	 	(b)	 correspond with ethics committees for purposes related to the Clinical Trial; 

 

	 	(c)	 handle, negotiate and sign site agreements and other agreements relating to the provision of clinical services
for the Clinical Trial on its behalf and/or, subject to approval by the Principal in writing, in the Principal’s name as its Attorney; 

  

	 	(d)	 monitor and manage the Clinical Trial; 

 

	 	(e)	 import any investigational medicinal product required for the Clinical Trial in accordance with the relevant
customs procedures; 

  

	 	(f)	 store and distribute materials related to the Clinical Trial; 

 

	 	(g)	 obtain export licenses for the Clinical Trial if required; 

 

	 	(h)	 assist the Principal to report serious adverse events related to the Clinical Trial to ethics committees in
accordance with local requirements; or 

  

	 	(i)	 collect any investigational medicinal product from sites at which the Clinical Trial is conducted and return to
the Principal or arrange for destruction as required by the Principal, 

 in each case, in accordance with and subject to
the Covance Master Services Agreement entered into between the Principal and the Attorney on [insert] relating to the conduct of the Clinical Trial. 
  

	 	1.2	 Except for those agreements referred to in Paragraph 1.1(c) above, the Attorney shall have no authority to
enter into any agreements in the name or on behalf of the Principal or otherwise act on behalf of or bind the Principal, and the Attorney shall not hold itself out as having authority to do the same. 

 

	 	1.3	 This Power of Attorney cannot be transferred or delegated by the Attorney to any other persons or entity.

  

	2.	 DURATION 

  

	 	2.1	 Subject to Paragraphs 2.2 and 2.3, this Power of Attorney shall be valid until completion of the Clinical Trial
in accordance with the protocol for the Clinical Trial. 

  

			
	Page 52 of 60

	 	2.2	 The Principal may revoke the Power of Attorney in relation to the Attorney with immediate effect by written
notice at any time to the relevant Attorney at the relevant address above. 

  

	 	2.3	 The Attorney may revoke the Power of Attorney with immediate effect in accordance with paragraph 9 of the
relevant work order forming part of the Agreement. 

  

	 	2.4	 The Attorney must immediately cease to exercise any of the powers granted by this Power of Attorney if this
Power of Attorney expires, terminates or is revoked by the Principal. 

  

	3.	 RATIFICATION 

The Principal undertakes to ratify and confirm whatever the Attorney does or purports to do in good faith in the exercise of any power
conferred by this Power of Attorney. 
  

	4.	 VALIDITY 

The Principal declares that a person who deals with the Attorney in good faith may accept a written statement signed by the Attorney to the
effect that this Power of Attorney has not been revoked as conclusive evidence of that fact. 
  

	5.	 LANGUAGE 

The official text of this Power of Attorney and any notices given hereunder shall be in English. If any dispute occurs concerning the
construction or interpretation of this Power of Attorney, reference shall be made only to the Power of Attorney as written in English and not to any translation into any other language. 

 

	6.	 JURISDICTION 

This Power of Attorney (and any dispute, controversy, proceedings or claim of whatever nature arising out of or in any way relating to this
Power of Attorney or its formation or any act performed or claimed to be performed under it) shall be governed by and construed in accordance with [insert relevant law]. 

[INSERT RELEVANT EXECUTION BLOCK] 

  

			
	Page 53 of 60

 EXHIBIT B2 - PRO-FORMA WORK ORDER: NO LEGAL
REPRESENTATIVE SERVICES 
 This WORK ORDER is made the date the last party signs below between: 

 

	(1)	 Galectin Therapeutics Inc. whose registered office is at Suite 240, 4960 Peachtree Industrial Boulevard,
Norcross, Georgia 30071 (the Sponsor); and. 

  

	(2)	 COVANCE [    ] whose registered office is at [insert address] (Covance),

 (each a Party and collectively the Parties). 

RECITALS 
  

	(A)	 WHEREAS Galectin Therapeutics Inc. (Sponsor) and Covance Inc. (the Company) are parties to a
Master Services Agreement effective as of March 12, 2020 (the MSA). 

  

	(B)	 WHEREAS Covance is a party to the MSA by virtue of Exhibit A-[ ] to the
Agreement [intent/language needs to be clarified about which Covance entity will be a party. Language suggest that the entity to sign this is not the party to the Master Agreement] 

 

	(C)	 WHEREAS subject to the terms and conditions of the MSA and the additional terms and conditions set forth in the
relevant Exhibit A, the Sponsor and Covance hereby agree to execute a Work Order relating to the Services for Sponsor’s Protocol/Scientific Plan [insert reference]. 

NOW THEREFORE the Parties agree as follows: 
  

	1.	 Definitions and Interpretation 

 

	1.1	 Each word and term used in this Work Order, but not defined, has the meaning specified in the Agreement unless
a clear contrary interpretation otherwise applies. 

  

	1.2	 In the event of conflict between the terms and conditions of this Work Order and those of the Agreement, the
terms of the Agreement shall prevail except to the extent that this Work Order expressly and specifically states an intent to supersede the Agreement on a specific matter. 

 

	2.	 Term and Termination 

 

	2.1	 The term of this Work Order [shall commence on ...] [shall be deemed to have commenced on ...] and shall
continue until completion of the Services or earlier termination of the Agreement in accordance with the termination provisions set out in the Agreement (the Term). 

 

	3.	 Services 

Covance agrees to perform the following Services for the Sponsor as set forth in the attached description of Services at Annex 1, which shall
also detail the Study/Services Specific Assumptions that apply to the Services. 
  

	4.	 Budget 

  

	4.1	 The Budget for the Services is set out in the detailed Budget in this Work Order attached at Annex 2.

  

	4.2	 In consideration for its performance of the Services under this Work Order, the Sponsor shall pay Covance in
accordance with the payment schedule or payment terms set out in this Work Order attached as Annex 3. 

  

			
	Page 54 of 60

	4.3	 Invoices are due within thirty (30) days of receipt by the Sponsor. 

 

	5.	 Payment and Invoice Details 

All invoices to the Sponsor should be sent to the following address: 

[insert] 
 All payments to Covance should
be sent to the following address: 
 [insert] 
  

	6.	 Change Control 

In the event that any of the Assumptions used to calculate the Budget or in the provision the Services change, in accordance with Section 10 of the MSA,
the Parties shall negotiate an amendment to this Work Order if appropriate. No amendment to this Work Order shall be binding unless agreed in writing. 
  

	7.	 Insurance [FOR COVANCE CLINICAL, CRU] 

[Sponsor hereby represents that insurance referred to in Paragraph 3 of Exhibit A-[ ] (Covance Clinical) of the
Agreement is applicable to and valid for the duration of this Study.] 
 [Sponsor hereby represents that insurance referred to in Paragraph 8 of Exhibit A-[ ] (CRU) of the Agreement is applicable to and valid for the duration of this Study.] 
  

	8.	 Entire Agreement 

This Work Order and the terms of the Agreement represent the entire and integrated agreement between the Sponsor and Covance and supersede all prior
negotiations, representations or agreements, either written or oral, regarding the Services. 
  

	9.	 Choice of Law and Jurisdiction 

Any contractual dispute or claim arising between the Parties to this Work Order arising out of or in connection with the Agreement or the Services defined
herein shall be construed, governed, interpreted, and applied in accordance with the provisions of Section 33.11 of the Agreement. 
  

									
	Galectin Therapeutics Inc.	 		 	Covance [    ].

									
					
	Signature 	 	 	 		 	Signature 	 	 
					
	Name:	 	 	 		 	Name:	 	 
					
	Title:	 	 	 		 	Title:	 	 
					
	Date:	 	 	 		 	Date:	 	 

  

			
	Page 55 of 60

 ANNEX 1 – DESCRIPTION OF SERVICES 

  

			
	Page 56 of 60

 ANNEX 2 – BUDGET 

[Wording for Covance Clinical: The pricing for the Work Order shall be deemed to be a Fixed [Unit] Price Work Order, which means a fixed set of Services and
delivered in accordance with the fixed [fees]/[unit budget] outlined in this Annex. 
 Additional paragraph for Fixed Unit Price: Fixed Unit Prices
reflect the average unit price to perform the task and are not illustrative of the actual effort associated with the unit. If the scope of an individual unit changes or the projected number of units are not achieved, adjustments shall be made to the
Fixed Unit Price or the development of a new unit (as the case may be) in accordance with Section 10 of the MSA to reflect the actual effort associated with the unit.] 

  

			
	Page 57 of 60

 ANNEX 3 – PAYMENT SCHEDULE OR PAYMENT TERMS 

  

			
	Page 58 of 60

 EXHIBIT C - PRO-FORMA CHANGE ORDER 

This CHANGE ORDER is made the date the last party signs below between: 
  

	(1)	 Galectin Therapeutics Inc. whose registered office is at Suite 240, 4960 Peachtree Industrial Boulevard,
Norcross, Georgia 30071 USA (the Sponsor); and. 

  

	(2)	 COVANCE [    ] whose registered office is at [insert address] (Covance),

 (each a Party and collectively the Parties). 

RECITALS 
  

	(A)	 WHEREAS Galectin Therapeutics Inc. (Sponsor) and Covance Inc. (the Company) are parties to a
Master Services Agreement effective as of March 12, 2020 (the MSA). 

  

	(B)	 WHEREAS Covance is a party to the MSA by virtue of Exhibit
A-[    ] to the MSA. 

  

	(C)	 WHEREAS the Sponsor and Covance are Parties to a work order effective as of [date] under the Agreement relating
to the Services (the Work Order). 

  

	(D)	 WHEREAS subject to the terms and conditions of the Agreement the Sponsor and Covance hereby agree to amend the
Work Order. 

 NOW THEREFORE the Parties agree as follows: 

 

	1.	 Scope and Definitions 

 

	 	1.1.	 Each word and term used in this Change Order, but not defined, has the meaning specified in the Agreement
unless a clear contrary interpretation otherwise applies. 

  

	 	1.2.	 Pursuant to Section 10 of the MSA, the Parties have agreed to vary the terms agreed in the Agreement or
Work Oder by the terms set out in this Change Order No #. 

  

	 	1.3.	 In the event of conflict, the terms in this Change Order shall take precedence over the Agreement or the Work
Order. 

  

	2.	 Term and Termination 

The term of this Change Order [shall commence on ...] [shall be deemed to have commenced on ...] and shall continue until completion of the
Services or earlier termination of the Agreement in accordance with the termination provisions set out in the Agreement (the Term).  
  

	3.	 Amendments 

  

	 	3.1.	 It has been agreed between the Parties that the Work Order shall be extended for a further term of ... until
..... 

  

	 	3.2.	 In consideration of agreeing to provide the Services as amended by this Change Order: 

 

	 	3.2.1.	 the description of Services (Annex 1) of the Work Order is hereby replaced in its entirety by revised
description of Services attached at Annex 1 of this Change Order. 

  

	 	3.2.2.	 the Budget attached at Annex 2 of the Work Order is hereby replaced in its entirety by the revised Budget
attached at Annex 2 of this Change Order. [The revised Budget reflects the revised description of Services and Study/Services Specific Assumptions contained in Annex 1 to this Change Order.] 

  

			
	Page 59 of 60

	 	3.2.3.	 the payment schedule (Annex 3) of the Work Order is hereby replaced in its entirety by the revised payment
schedule attached at Annex 3 of this Change Order. 

  

	 	3.3.	 In all other respects the Agreement and the Work Order shall continue in full force and effect.

 SIGNED in duplicate by an authorised signatory for and on behalf of: 

 

									
	Galectin Therapeutics Inc.	 		 	Covance [    ]

									
					
	Signature 	 	 	 		 	Signature 	 	 
					
	Name:	 	 	 		 	Name:	 	 
					
	Title:	 	 	 		 	Title:	 	 
					
	Date:	 	 	 		 	Date:	 	 

  

			
	Page 60 of 60

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]